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SUMMARY 
Interleukin-1 (IL-1) is involved in the pathogenesis of coronary artery disease 
(CAD) and restenosis. IL-1 receptor antagonist (IL-1 ra) blocks IL-1 signalling 
by competitive binding to the Type 1 IL-1 receptor. IL-1 ra has been used 
successfully to modulate inflammatory diseases but its effect on coronary 
artery injury or restenosis is unknown. An alternative therapeutic target for 
inhibition of IL-1 is the human soluble type II IL-1 receptor. However, 
assessment of its binding capacity for porcine IL-1 using surface plasmon 
resonance technology determined that the human type II IL-1 R could not bind 
porcine IL-1, thereby preventing its use in this work. This work therefore 
aimed to examine the effect of IL-1 ra on the porcine coronary response to 
injury. 
Initial pharmacokinetic studies in pig skin determined the inhibitory plasma 
level of IL-1 ra; an intravenous bolus of 0.5mg/kg followed by a 14-day 
continuous subcutaneous infusion of 2mg/kg/24h. Five groups of animals 
were studied, all being randomised to either IL-1 ra or vehicle according to the 
above protocol. Group 1: 12 pigs underwent oversized (1.25:1) angioplasty of 
2 coronary vessels. Analysis was at 28 days. Groups 2, 3,4 and 5 underwent 
coronary stenting (1.25: 1). Group 3 was analysed at 14 days, Groups 2 and 4 
at 28 days and Group 5 at 90 days. Histomorphometric measurements were 
made. A further group of animals were studied in which the IL-1 ra was 
infused for 14 days and analysis was at 17 days in order to determine vessel 
wall levels of IL-1 by real time PCR. 
25 
After an initial early peak, plasma levels of IL-1 ra ranged from 150 - 250ng/ml 
for the 14-day infusion. In Group 1, IL-1 ra resulted in a 23% decrease in 
intima:media ratio normalised to intemal elastic lamina fracture length (0.044 
± 0.005 vs. 0.057 ± 0.004; P = 0.01). Group 2 showed a 34% increase in 
neointimal area (0.38 ± 0.04 vs. 0.25 ± 0.02mm2; p = 0.001) in the IL-1 ra 
treated animals. Contrastingly, in Groups 3, 4 and 5, there was a 33%, 38% 
and 41 % decrease in neointimal area (0.16 ± 0.1 vs. 0.26 ± 0.16 mm2; p < 
0.0001; 0.19 ± 0.07 vs. 0.29 ± 0.19 mm2; p < 0.0004; 0.13 ± 0.01 vs. 0.22 ± 
0.01 mm2; p < 0.000001 respectively). No differences in IL-1 levels in the 
vessel wall were detected 3 days after cessation of IL-1 ra therapy. 
In porcine coronary arteries, IL-1 ra was associated with a significant reduction 
in neointima formation when vessels underwent oversized balloon angioplasty 
and following stenting for the duration of the infusion and when the infusion 
was continued for 28-days. However, in the stent model there was an 
increase in neointima formation after discontinuation of the infusion, which is 
not explained by an increase in vessel wall IL-1. Thus, IL-1 ra shows excellent 
promise as a new therapy for inhibition of neointima formation. This work has 
shown that at least 28 days of therapy is needed. 
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CHAPTER ONE 
INTRODUCTION 
1.1 Atherosclerosis 
1.1.1 Definition 
Complications of atherosclerosis are the most common causes of death in the 
westem world. The term atherosclerosis originates from the Greek, athere 
(meaning 'gruel'), which describes the soft, lipid rich core of the plaque and 
skleros (meaning 'hard') that describes the hard fibrous capsule that 
surrounds the core. Gresham defined atherosclerosis in 1986 as ' a disease 
of the arteries in which fatty plaques develop on their inner walls, with 
eventual obstruction of blood flow' [1]. The term atherosclerosis is now 
synonymous with coronary heart disease (CHD) [2]. 
1.1.2 Pathophysiology of atherosclerosis and the role of inflammation 
Research over the last two decades has provided convincing evidence that 
inflammation plays a key role in the initiation and progression of coronary 
heart disease [3] and that atheromatous plaque disruption is directly related to 
the development of acute coronary syndromes. 
Both Ross [3] and Glass [4] have described the vessel wall response to injury 
in detail. The earliest events in the pathogenesis of atherosclerosis are 
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thought to be injury to the arterial intima and oxidation of low density 
lipoprotein (LDL) in the subintimal space [5]. This results in an inflammatory 
reaction that leads to the release of cytokines and chemoattractant molecules. 
These molecules are responsible for the recruitment of neutrophils and 
monocytes from the circulation and their adhesion to the vascular wall. 
There are different stages in the development of an atherosclerotic plaque, 
the starting point of which is now thought to be endothelial cell dysfunction [3] 
which leads to compensatory mechanisms that change the normal 
homeostatic properties of the endothelium. Permeability of the endothelium 
and its "stickiness" with respect to platelets and leukocytes is altered. The 
endothelium loses its anticoagulant effect, becoming procoagulant, forming 
and releasing cytokines (e.g. Interleukin-1) and vasoactive molecules. An 
intermediate plaque forms secondary to smooth muscle cell migration and 
proliferation within this area. This results in the artery wall becoming 
thickened. An atherosclerotic plaque in its immature form starts as a fatty 
streak that is a purely inflammatory lesion. This process continues with time, 
resulting in the formation of an atherosclerotic plaque. The artery 
compensates by gradually dilating (remodelling) which allows the artery lumen 
diameter to remain essentially unchanged despite a relatively large amount of 
disease [6]. Continued inflammation results in increased numbers of 
macrophages and lymphocytes from the blood entering the lesion. Again, 
activation of these leads to further cytokine release, which in tum cause 
further cell accumulation and may even result in necrosis. The cycle repeats 
itself with migration and proliferation of smooth muscle cells and consequent 
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formation of fibrous tissue. The lesion (now termed advanced or complicated) 
enlarges, eventually becoming covered with a fibrous cap. The compensatory 
dilatation of the artery at some point fails to keep up and the plaque then 
encroaches into the lumen and alters the flow of blood causing ischaemia. 
Inflammatory processes within the plaque continue and may result in a 'stable' 
plaque becoming 'unstable'. In an unstable plaque, lymphocytes activate 
macrophages resulting in increased expression of matrix metalloproteinases 
that cause collagen degradation and thinning of the fibrous cap. Thinning and 
rupture of this cap is the most common cause of intracoronary thrombus. 
1.1.3 Factors responsible for endothelial cell dysfunction 
Possible causes of endothelial cell dysfunction which lead to atherosclerosis 
include elevated blood lipids (especially LDL) [7], genetic predisposition [3], 
smoking [8] and diabetes [9] which lead to the formation of free radicals. In 
addition, more recent studies have implicated infectious microorganisms such 
as Chlamydia pneumoniae [10]. 
1.1.4 Plaque rupture 
Advanced atherosclerotic lesions lead to ischaemic symptoms due to 
progressive lumen narrowing. It is plaque rupture however that results in 
clinically significant acute coronary syndromes or acute myocardial infarction. 
Plaque rupture exposes plaque lipids to blood components. This results in 
the initiation of the coagulation cascade and consequent platelet aggregation 
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and thrombosis. Post mortem analyses of atherosclerotic plaques suggest 
that small ruptures occur recurrently with evolution of the plaque but not all 
are clinically significant. Clinically significant ruptures usually involve the part 
of the plaque with a thin fibrous cap and large necrotic core. The risk of 
plaque rupture seems to depend upon plaque morphology rather than size or 
degree of stenosis [11]. Fibrosis with VSMC proliferation and collagen 
synthesis leads to hardening of the plaque whereas inflammation leads to 
fibrous cap degradation, which predisposes to plaque rupture. 
1.2 Interleukin-1 and atherosclerosis 
1.2.1 Cytokines 
'Cytokines are regulatory proteins secreted by white blood cells and a variety 
of other blood cells in the body; the pleiotropic actions of cytokines include 
numerous effects on cells of the immune system and modulation of 
inflammatory responses' [12]. Interleukin 1 (IL-1) is a member of the cytokine 
family. The term interleukin was proposed by Aarden et al in 1979 in order to 
develop 'a system of nomenclature ... based on (the proteins) ability to act as 
communication signals between different populations of leukocytes' [13]. 
Although the name 'interleukin' implies that these agents act as 
communication signals between leukocytes, the term is not solely reserved for 
factors that can only act upon leukocytes. 
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1.2.2 The Interleukin-1 (IL-1) family 
The majority of nucleated cell types secrete interleukin-1. It has a wide range 
of effects and exerts these on most cell types, often in combination with other 
cytokines. The IL-1 family is made up of 3 different members: IL-1 alpha (IL-
1a), IL-1beta (IL-1(3) and IL-1receptor antagonist (IL-1ra). A separate gene 
encodes each member of the family. Cells that secrete IL-1 express the 
genes for all types but which one is secreted depends upon the level of 
expression of each gene. The IL-1 agonists, IL-1a and IL-1(3, are structurally 
distinct. In most studies, the effect of their biological activity is 
indistinguishable. Both are 17-kD proteins coded by separate genes on 
chromosome 2. The IL-1 a and (3 proteins are synthesized by a variety of cell 
types including activated macrophages, stimulated lymphocytes and 
fibroblasts and are both potent mediators of inflammation and immunity. Both 
IL-1a and (3 are synthesized as precursors with a molecular weight of 31kDa. 
Splicing of these into mature active forms requires specific cellular proteases. 
There are 2 receptors for IL-1. The type I receptor (IL 1 R1) is a signalling 
receptor (affinity IL-1 ra>IL-1 a>IL-1 (3), whereas the type" receptor (IL 1 R2) is a 
decoy receptor (affinity IL-1(3)IL-1a>IL-1ra) [14]. 
1.2.3 Interleukin-1 alpha (IL-1 a) 
The IL-1a precursor (ProIL-1a) is biologically active and is synthesized in 
association with microtubules and translated in the endoplasmic reticulum 
[15]. Because it lacks a leader peptide, there is no appreciable accumulation 
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of IL-1a in any organelle and it remains in the cytosol. Immunohistochemical 
studies of IL-1a in endotoxin-stimulated human blood monocytes reveal a 
diffuse staining pattern that is localised to the Golgi apparatus. IL-1a, unlike 
IL-1 ~ is not usually found in the circulation or in body fluids (presumably 
because of its cell associated nature), except during severe disease in which 
case it is most likely released from dying cells. 
1.2.4 Interleukin-1 beta (IL-1 P) 
The IL-1 ~ precursor (ProIL-1~) is not biologically active but is secreted as a 
result of cleavage of IL-1 ~ by Interleukin -1 ~ converting enzyme (ICE) [16]. 
Depending on the stimulus, 15 minutes after activation, IL-1 ~mRNA levels rise 
rapidly and continue to do so up to 4 hours after which time levels begin to 
fall. Stimulants such as hypoxia [17] or complement (component C5a) [18] 
induce the synthesis of large amounts of IL-1~mRNA in monocytes, although 
most of the mRNA produced gets degraded and is never translated into the 
IL-1 ~ protein. It appears that the IL-1 ~mRNA needs to be stabilized before 
translation happens. There are many different mechanisms by which this 
occurs, and auto stabilization or stabilization by microbial products are 2 
possibilities. The release of IL-1 from activated immune cells requires a 
secondary stimulus such as extracellular ATP acting on P2X7 receptors. 
Activation of these receptors leads to the shedding of microvesicles that 
contain bioactive IL-1 ~ [19]. 
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1.2.5 Interleukin -1 receptor antagonist (IL-1 ra) 
IL-1 ra is a specific receptor antagonist of IL-1 and is the only known naturally 
occurring cytokine antagonist. IL-1 ra is secreted in 2 forms, the first (a 
secreted form of IL-1 ra (sIL-1 ra», has a signal peptide and the profile of an 
acute phase reactant [20]; the second (the intracellular form (icIL-1 ra», has a 
number of subtypes, none of which have a signal peptide. IL-1 ra is the 
molecule responsible for the blockade of the type 1 IL-1 receptor (IL-1 R1). 
Pro1L-1 ra possesses a leader sequence and is synthesised, processed and 
secreted from the cell. Data from our laboratory suggests that this may be via 
a P2X7 receptor system [21]. In pharmacological studies, IL-1 ra is required in 
100 fold excess proportions to IL-1~ to block its effects [14]. There is 
evidence that disease outcome may be regulated by the balance between IL-
1 ~ and IL-1 ra. IL-1 ra has been shown to block the inflammatory responses 
induced by IL-1 both in vivo and in vitro. 
1.2.6 The Interleukin-1 Receptors 
There are two primary Interleukin-1 receptors (Type-1 (IL-1 RI) and Type-II (IL-
1 RII», and one accessory protein (IL-1 R-AcP). The two receptors are distinct 
gene products with both genes situated on the long arm of chromosome 2 
[22]. IL-1 RI is an 80kDa transmembrane protein and is the primary signal 
transducing receptor [23]. IL-1 R-AcP is essential for IL-1 signalling via the IL-
1 RI [24]. IL-1 initially binds to the type-1 receptor with low affinity. Once 
bound, it is thought a structural change takes place that allows binding of the 
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IL-1 R-AcP. Any subsequent binding of IL-1 then occurs with high affinity [25]. 
Although IL-1 ra binds to the IL-1 RI, no complex forms and therefore no 
Signalling (agonist activity) occurs. The IL-1 RII is a 68kDa membrane protein 
that lacks a cytosolic signal transducing domain and therefore remains 
functionally negative, acting as a decoy receptor. It preferentially binds IL-1 p, 
preventing its binding and therefore signalling via the IL-1 RI [26]. It is worth 
noting that in primary cells, there are less than 100 IL-1 RI per cell and a 
biological response occurs when as few as 2-3% of them are occupied [27]. 
1.2.7 The role of Interleukin-1 in atherosclerosis 
There are multiple potential sources of IL-1 at the time of arterial injury. 
Adherent platelets may produce IL-1 , as well as the recruited inflammatory 
cells. In addition endothelial cells, which re-grow and cover the site of injury 
may also produce IL-1. IL-1 has many inflammatory effects upon endothelial 
cells and vascular smooth muscle cells, plausibly associated with neointima 
formation and notable amongst these is the autocrine induction of PDGF by 
vascular smooth muscle cells [3]. A role for IL-1 in atherosclerosis was 
confirmed when IL-1 J3 mRNA was detected in human atherosclerotic plaques 
[28]. Subsequent work showed that treatment of porcine arteries with IL-1 J3 
induced intimal lesions [29]. IL-1 J3 mRNA and protein have also been 
detected in coronary arteries of patients with ischaemic heart disease [30]. 
After experimental injury, IL-1 J3 mRNA is present in porcine coronary arteries 
within 1h of injury and persists up t018h. IL-1J3 protein, detected by 
immunohistochemistry is localised to the luminal endothelium and has peak 
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expression between 3 and 14 days post-PTCA [31]. Recktenwald et a/ have 
shown that mice deficient in the type 1 IL-1 receptor gene develop less 
neointima than wild-type mice [32]. These studies lead to the hypothesis that 
locally generated IL-1 ~ may contribute to atherosclerosis and the vascular 
response to balloon injury. 
1.2.8 Interleukin-1 administered to humans 
IL-1a and IL-1~ have both been administered to humans. Subcutaneous 
injection was associated with significant local pain, erythema and swelling [33] 
and patients given a continuous intravenous infusion experienced a febrile 
response that increased in magnitude with increasing dose of IL-1. Nearly all 
patients receiving intravenous IL-1 at a dose of 100 ng/kg or greater 
experienced significant hypotension [34]. These studies confirmed the 
pyogenic and hypotension inducing properties of the molecule. 
1.2.9 The role of IL-1 ra in atherosclerosis 
Several studies on IL-1 ra have provided further evidence for the IL-1 family 
and its role in atherosclerosis. For example, IL-1 ra inhibits the formation of 
intimal fatty streaks in apolipoprotein E-deficient mice [35] and IL-1 ra 
knockout mice have been shown to spontaneously develop arterial 
inflammation [36]. A recent study by Isoda et a/ used knockout mice to test 
the hypothesis that IL-1 ra was directly involved in neointima formation. They 
showed that the absence of IL-1 ra promotes neointima formation in the 
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mouse model and provides more evidence for the role of IL-1 and IL-1 ra in the 
vessel wall response to injury. In patient studies, plasma concentrations of IL-
1 ra are elevated in patients with atherosclerosis and levels correlate well with 
disease occurrence [37]. In addition, circulating levels of IL-1 ra following 
acute myocardial infarction are elevated [38]. Interestingly, those patients 
with in-patient complications had a higher serum IL-1 ra levels on admission. 
1.2.10 Interleukin-1 receptor antagonist and amelioration of disease 
Several clinical trials have used IL-1 receptor antagonist, the natural inhibitor 
of IL-1, in the treatment of disease with clinical success [39, 40]. However, 
none of these have studied its effect on coronary heart disease. A consistent 
observation in these trials is a reduction in the number of infiltrating 
neutrophils associated with local inflammation [41]. IL-1 ra has been given to 
patients, with amongst other things, graft versus host disease and rheumatoid 
arthritis. A large double blind vehicle-controlled trial of IL-1 ra in 472 patients 
with rheumatoid arthritis resulted in a dose-dependent reduction in the 
number of swollen joints and overall assessment of patient scores (p=0.048) 
[39]. Doses used ranged from 30 - 150mg/24h for 24 weeks, with no 
demonstrable side effects from the IL-1 ra. A study looking at steroid resistant 
graft versus host disease used doses as high as 3400mg/24hr for 7 days with 
improvement in 16 out of 17 patients and no side effect profile [42]. Studies 
have shown IL-1 ra to be safe when given to humans at high concentration 
(10mg/kg over 3 hours) [43]. 
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1.3 Cardiac manifestations of atherosclerosis - coronary heart 
disease 
1.3.1 Incidence of coronary heart disease 
Cardiovascular disease is the most frequent cause of death amongst adults in 
developed countries. Coronary heart disease, the most common cause of 
death in the UK accounted for around 125,000 deaths in the UK in 2000, 
approximately 1 in 4 deaths in men and 1 in 6 deaths in women. It accounts 
for 26% of premature deaths in men and 16% in women. Approximately 1.5 
million people suffer from angina in the UK (British Heart Foundation data, 
2000). Using 1999 CHD mortality data from the Office for National Statistics, 
it has been estimated that 149,000 men and 125,000 women per year in the 
UK will have a myocardial infarction. In the USA, the Framingham study has 
shown the incidence of CHD is 5 per 1000 men per year aged 35 - 44 years, 
increasing to 59 per 1000 men per year aged 85 - 94 years. Women lag 
behind men by approximately a decade until after the menopause when the 
difference reduces. Heart disease in the UK is a Significant problem, costing 
an estimated £10 billion per annum, including loss of earnings, disability 
benefit and the costs of caring, of which £1.6 billion is spent directly on health 
care (British Heart Foundation figures, 1998). 
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1.3.2 'Angina Pectoris' (angina) 
The clinical manifestation of coronary heart disease is angina pectoris. 
Heberden first used this term in 1768 to describe 'a painful and most 
disagreeable sensation in the breast, which seems as if it would extinguish 
life, if it were to increase or continue' . It was not until 1786 after participating 
in post-mortems of people who had died from angina that Jenner proposed it 
was due to 'a kind of firm fleshy tube, formed within the vessel, with a 
considerable quantity of ossific matter dispersed irregularly through It " what 
we now understand to be atherosclerosis (the reader is again referred to the 
review of the history of CHD by Fye) [44]. There are four clinically recognised 
syndromes of angina; stable, unstable, Prinzmetals and Syndrome X. The 
first two are by far the commonest. Unstable angina is defined as unprovoked 
angina (at rest). Prinzmetals angina is a rare syndrome in which vasospasm 
occurs, usually at a site of minimal disease causing ST segment elevation on 
the ECG. Syndrome X encompasses angina, a positive test of provoked 
ischaemia (for example an exercise test) and angiographically normal 
coronary arteries. The cause is unclear but thought to be secondary to 
disease of small coronary vessels [45]. 
1.3.3 Patho-physiologic mechanisms in stable and unstable angina 
Stable angina is most commonly related to an increase in myocardial oxygen 
demand triggered by physical activity. During exercise, when the demand by 
the myocardium for oxygen is greater, homeostatic mechanisms are activated 
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that lead to vasodilatation resulting in increased coronary artery diameter and 
consequent oxygen supply. Invariably, in patients with angina, a fixed 
coronary artery obstruction is present (Le. an atherosclerotic plaque) which 
limits oxygen delivery during times of increased metabolic demand. Non-
occlusive coronary thrombi (caused by unstable or 'ruptured' coronary 
plaques) are usually present in patients with unstable angina and cause an 
acute impairment in oxygen delivery. The neural pathways involved in angina 
have not been established, although sympathetic afferent nerves are thought 
to be involved. 
1.3.4 Clinical presentation of stable and unstable angina 
It is well established that many people have stable atherosclerotic plaques 
within their vasculature that remain so for years. These only cause symptoms 
of angina when they grow large enough to narrow the arterial lumen and 
impede blood flow. At necropsy, patients who have had chronic stable angina 
for years usually have one or more coronary arteries reduced by 50% in 
diameter [46]. The definition of angina is largely based on the clinical 
presentation. Stable angina pectoris is characterised by chest or arm 
discomfort associated with physical exertion, emotional stress or cold weather 
that is relieved by a short period of rest or sublingual nitroglycerin. Unstable 
angina is a poorly defined syndrome and describes a very heterogeneous 
population of patients with single or multi-vessel disease, with or without prior 
myocardial infarction. It includes patients with one of the following: (1) chest 
pain that occurs at rest (or with minimal exertion) lasting more than 20 
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minutes (2) a severe and frank pain of new onset (Le., within one month) and 
(3) a pain that occurs with a crescendo pattern [47]. Unstable angina results 
from plaque that becomes unstable and prone to rupture due to episodic 
inflammatory events (see 1.1.2), resulting in the development of intracoronary 
thrombus and an acute coronary syndrome (an episode of chest pain that 
represents either unstable angina or myocardial infarction). 
1.3.5 Treatment of stable angina 
Pharmacological therapy with aspirin, nitrates and ~-blockers provides the 
mainstay of treatment. Initial attempts at the surgical treatment of CHD were 
unsuccessful and it wasn't until the 1960s that Favoloro's procedure of aorto-
coronary bypass grafting (CABG) under cardio-pulmonary bypass provided a 
successful, safe method of angina treatment. Initial operations were 
performed using the internal mammary artery and, as the technique 
developed, autologous saphenous veins were used. More recently, gastro-
epiploic and radial arteries have been used. These developments have made 
the operation even more safe and successful. Other surgical approaches 
include sympathectomy and, in extreme cases, cardiac transplantation [48]. 
Since the 1980s, percutaneous revascularisation (percutaneous coronary 
intervention (PCI» has also become a treatment option providing an 
alternative to surgery. 
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1.3.6 Indications for PCI and CABG 
The clinical indication for revascularisation is poor symptom control by 
medical therapy. Over the last few years, due to advancements in the 
equipment available and increased operator experience, the indications for 
PCI have changed, encompassing a wider remit. A number of randomised 
trials have directly compared the efficacy of PCI and CABG in single and 
double vessel disease, with discrete stenoses (RITA 1993, BAR I 1996, EAST 
1994 to name a few). For a review of medical therapy vs. PCI vs. CABG see 
Kurbaan et al. [49]. In general, these studies revealed similar mortality figures 
(2 - 3% at one year), except in diabetic patients, who experience a higher 
mortality after PCI than CABG, within the limitations of the inclusion criteria. 
The difference was seen in the excess of re-interventions in the PCI group, 
reflecting both clinical and angiographic restenosis. There are no data on 
long-term follow-up but these will be important, because the mortality of re-do 
CABG is greater than first time operation; and PCI is easily repeatable at 
relatively low risk. With the advent of drug-eluting stents, the balance has 
now firmly tipped towards PCI. 
1.3.7 Anti-inflammatory treatment strategies 
The effects of anti-inflammatory treatment in unstable angina are unknown. It 
is well established that aspirin-like drugs are good anti-inflammatory agents, 
related to their action on cyclo-oxygenase. A potential beneficial effect of 
aspirin on the prevention of acute coronary syndrome was suggested by 
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Ridker et a/ [50]. They found that when apparently healthy men received 
aspirin, they had significantly fewer episodes of myocardial infarction during 
follow-up. This reduction was significantly associated with CRP levels. The 
greatest decrease in risk of future events was in those men with a high 
baseline C- reactive protein who received aspirin. 
Numerous trials have shown that treatment with a statin (a cholesterol 
lowering agent) reduces the rate of major coronary events [51]. One 
beneficial effect of statins is their lowering of LDL-cholesterol, although 
pravastain and cerivastatin have both been shown to reduce macrophage 
accumulation and matrix metalloproteinase expression in atherosclerotic 
plaques [52, 53]. These observations have lead many to believe that there 
are non-lipid related mechanisms of statin action that include an anti-
inflammatory effect. Many believe that anti-inflammatory strategies may help 
to reduce the incidence of coronary heart disease although, to date, none 
have been tested. 
1.4 Percutaneous coronary intervention (PC I) 
1.4.1 Percutaneous coronary intervention - an historical perspective 
Percutaneous coronary intervention (PCI) comprises percutaneous 
transluminal coronary angioplasty (PTCA) and coronary stent implantation. 
Andreas Gruntzig, published his initial PTCA results in 1978 and pioneered 
the technique. Stent implantation has become commonplace since the mid-
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1990s and technology in this area continues to grow. Although catheter 
based techniques of revascularisation have an initial success rate that 
exceeds 95%, the immediate benefit is still attenuated by restenosis (the 
return of clinical symptoms following an apparently successful intervention) 
that occurs over the following 6 months. 
1.4.2 Proposed patho-physiologic mechanisms of PTCA 
The original explanation given by Gruntzig for enlargement of a vessel lumen 
by PTeA was compression of plaque [54] but this is now thought to be a 
minor effect. Other contributing factors are the extrusion of liquid components 
of the soft plaque and cracking of the intimal plaque with resultant stretching 
of the media and adventitia (layers of the arterial wall) and expansion of the 
outer diameter of the vessel. Waller studied post mortem specimens derived 
from 76 PTeA sites in 66 patients who died following PTeA and found 
evidence of superficial intimal cracks in 16%, deeper cracks with medial 
dissection in 73%, extensive medial dissection in 7% and adventitial 
perforation in 3% [55]. He went on to state that five basic mechanisms are 
involved in PTeA: plaque compression; focal plaque tear; stretching of the 
contralateral normal segment of arterial wall; stretching of the whole artery 
with little plaque compression; and dissection. These mechanisms have been 
confirmed by intravasular ultrasound (IVUS) imaging [56]. 
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1.4.3 Limitation of PTCA 
The major drawback of PTCA is that up to 40% of patients return with 
symptomatic restenosis. Restenosis is a multifactorial process, and features 
an excessive neointimal (smooth muscle cell) response to injury, recoil of the 
artery and negative remodelling (in which the restenosing artery gets smaller 
rather than bigger to accommodate the intraluminal tissue). It therefore 
follows that forming and maintaining a large arterial lumen will reduce the 
impact of restenotic tissue on blood flow. One method of doing this is to 
implant a coronary stent, which scaffolds the artery thereby eliminating recoil. 
1.4.4 Intracoronary stenting 
Over 90% of PCI performed in the UK today involves the implantation of an 
intralumenal stent. Traditional coronary stents are bare-metal (stainless-steel) 
cages that scaffold the artery, stabilise the plaque and help to prevent arterial 
recoil and therefore restenosis. BENESTENT 1 and STRESS, two early but 
significant clinical trials, clearly showed that stenting in native vessels reduced 
the incidence of restenosis compared with PTCA alone [57, 58]. Stents 
eliminate acute recoil of the vessel but, unfortunately, neointima formation still 
Occurs. It is worth noting that stenting actually results in more neointima 
formation than PTCA, but has an overall lower restenosis rate because of the 
prevention of unfavourable remodelling. In-stent restenosis using conventional 
bare metal stents occurs in 20 - 30% of patients (depending upon lesion and 
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patient type). A cure has proved elusive and, until a few years ago, remained 
one of the big outstanding challenges for investigators. 
1.5 Restenosis after PCI 
1.5.1 Clinical and angiographic Restenosis 
RestenosiS, an iatrogenic phenomenon, is commonly referred to 'as the 
process where a stenotic coronary artery, which regained significant patency 
following mechanical intervention, reverts to its former state of insufficient 
lumen diameter (practically :i! 50% loss of the gain by PTCA or stent) 1[59]. 
Of the 169 patients who underwent PTCA by Gruntzig, 31% required re-PTCA 
because of restenosis [60J. Since that time, for patients who undergo PTCA 
without placement of a stent, the number experiencing restenosis has not 
dramatically altered [61J. In studies that examine rates of restenosis following 
PCI, a distinction is made between clinical and angiographic restenosis, the 
former being those patients who require re-intervention because of re-
presentation secondary to symptom recurrence, and the latter those in which 
restenosis is noted at follow-up angiography but is not clinically apparent to 
the patient. There are problems with these definitions: clinical restenosis is 
subjective and angiographic restenosis has been described in many different 
ways, resulting in differing rates that depend on the definition used. An 
example of angiographic restenosis following PTCA is shown in Figure 1. In 
studies, angiographic definitions are usually required and usually comprise a 
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categoric definition such as diameter stenosis ~ 50% at follow-up and also a 
continuous one such as late loss [62]. 
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Figure 1 The angiographic appearance of restenosis 
(a) A tight localised stenosis in the left anterior descending artery is shown. 
(b) The appearance of the lesion following insertion of a stent. 
(c) Restenosis in the same lesion six months after initial stent deployment. 
47 
1.5.2 Time-course of restenosis 
Two landmark studies in 1988 defined the time-course of restenosis. Both 
performed serial quantitative angiography after PTCA. The study by 
Nobuyoshi et a/ [63] followed patients to 4 months post-procedure, and that by 
Serruys et a/ [64] to 12 months. In both studies, over three to four months, 
the mean minimum lumen diameter (MLO) decreased by 20% and the 
reference diameter by 10%. There was no further reduction after that time. 
Future studies showed that restenosis is complete by six months [65]. 
1.5.3 Pathogenesis of restenosis 
Information about restenosis at a cellular level has come from examination of 
tissue sections following atherectomy and at post mortem. Coronary 
angioscopy immediately following PTCA has shown plaque fissures and tears 
with mural thrombus in 70 - 80% of arteries despite the use of anticoagulant 
therapies [66]. Arterial tissue from atherectomy confirms that mural thrombus, 
intimal vascular smooth muscle cell (VSMC) and fibroblast proliferation occur 
within the first month of PTCA. Following these initial events, collagen and 
extracellular matrix (most likely synthesised by the VSMCs and fibroblasts) 
are more abundant. Thus, restenosis is a multi-factorial process. 
In summary, the following events contribute to restenosis. Angioplasty 
causes vascular injury. This results in the exposure of the internal elastic 
lamina of the vessel, which is a thrombogenic surface. This promotes platelet 
48 
aggregation and adhesion that release cytokines and growth factors and 
attract Circulating inflammatory cells, which adhere to and migrate into the 
already formed thrombus [67]. The initial events are therefore thrombosis and 
inflammation. Following this, granulation occurs where recruited VSMCs 
proliferate. Finally, a fibrous matrix forms, consisting of collagen and 
proteoglycans. Restenosis is localised to the site of balloon injury and its 
adjacent segment [55]. 
1.5.4 The importance of inflammation in restenosis 
Inflammation occurs early on following angioplasty or stent insertion. 
Neutrophils, lymphocytes and monocyes have been detected within the mural 
thrombus seen following angioplasty in a rabbit model [68]. Both traumatic 
arterial injury following PTCA, or stent placement and subsequent 
inflammation, therefore contribute to neointima formation. Farb et a/looked at 
the time-course of the histopathological response to stenting and showed that 
fOllowing stent insertion, there was fibrin, platelets and an acute inflammatory 
infiltrate around the stent struts. Over time, a chronic inflammatory infiltrate is 
evident [69]. Kornowski et al found a direct correlation between the 
inflammatory score (a score they devised to describe the extent and severity 
of an inflammatory cell infiltrate around metallic stent struts) and the degree of 
Subsequent arterial injury and neointimal thickness [70]. At a cellular level, a 
Single nucleotide polymorphism of the MAC-1 (CD11 b/CD18) leukocyte 
integrin receptor has been shown to have a strong association with the 
incidence of restenosis [71]. 
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The inflammatory process following PCI seems to be both specific to the site 
of injury and systemic. The local inflammatory response has already been 
described (see section 1.5.4). Evidence for a systemic response has been 
provided by several studies. Danenberg et at. demonstrated that 
administration of systemic bacterial lipopolysaccharide to a rabbit undergoing 
balloon angioplasty, resulted in increased neointima formation [72]. This 
effect was probably due to systemic activation of circulating leukocytes. A 
correlation of neointimal growth and systemic inflammation by the 
measurement of blood IL-1 f3 levels and the measurement of intimal growth 
was performed. In support of the role of inflammation, Schillinger et at. 
demonstrated that baseline and 48-hour post-procedure CRP levels were 
independent predictors of restenosis at 6-months following PCI [73]. 
1.5.4 Anti-inflammatory approaches to restenosis 
Several anti-inflammatory strategies have been successful in inhibiting 
restenosis in animal models. IL-10 has been shown to inhibit neointima 
formation following both PTCA and stenting in hypercholesterolaemic rabbits 
and, by using an antibody directed against the f32-integrin Mac 1 
(CD11 b/CD18) in the rabbit model, neointima formation has also been 
reduced [74]. In a pig model, Wang et al showed that pre-treatment of 
animals with an antibody to P-selectin glycoprotein ligand (PSGL - the ligand 
for P-selectin on leukocytes) prior to balloon angioplasty significantly reduced 
neointima formation at 28-days [75]. 
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The importance of an anti-inflammatory approach to atherosclerosis has 
already been discussed (see 1.3.8). From those data presented above, there 
is also significant evidence that inflammation plays an important role in the 
induction and continued formation of neointima. It follows therefore, that an 
anti-inflammatory approach to restenosis would be an attractive target for its 
prevention. 
1.5.5 Current approaches to restenosis 
Therapeutic approaches to restenosis may be preventative or therapeutic (Le. 
treating the restenosis once it has occurred). The former approach is 
preferable as disease is always harder to treat once established. In order to 
help prevent restenosis, the angiographic result obtained during the 
procedure should be as good as possible with accurate stent sizing and as 
little damage to adjacent tissue as possible should occur. Despite all 
precautions, restenosis will still occur in a significant number of patients. 
Pharmacological approaches to inhibit restenosis have been developed and 
have focused on four main strategies; anti-proliferative; anti-inflammatory; 
anti-migratory and pro-endothelial. Systemic and local delivery approaches 
have been studied and are described further in 1.6. The work in this thesis 
has concentrated on an anti-inflammatory strategy to prevent restenosis. 
51 
1.5.6 In-stent restenosis - current treatment options 
There are now two major treatments for in-stent restenosis. The first, called 
vascular brachytherapy is a secondary measure that is used once restenosis 
has developed. This technique reduces restenosis within an artery by about 
60%, irrespective of whether p-emitting or y-emitting radiation is used. 
However, radiation has safety issues and is limited by geographical miss (an 
area of restenosis that does not receive radiation therapy), edge of stent 
restenosis and late stent thrombosis. Primary preventative strategies have 
concentrated on eliminating restenosis at a cellular level. Different 
approaches have been tried, including anti-proliferative, anti-migratory, anti-
inflammatory and pro-endothelial (healing) strategies. Agents that seemed 
promising following in vitro and in vivo animal studies often failed to translate 
into clinical efficacy in man. The reasons for these failures were unclear. It 
was not until a stent-based, local delivery system using a biologically inert 
polymer to release the drug (called a drug-eluting stent) was employed that 
results dramatically improved and clinical benefits were seen. 
1.5.8 Drug-eluting stents 
The first drug-eluting stent (Cypher™, Cordis) was recently made 
commercially available in the UK. Data from the RAVEL study and the 'First-
in-man' study show that this device, which elutes the drug Sirolimus 
(Rapamycin), continues to produce a zero restenosis rate up to, and beyond, 
one year in selected lesions [76, 77]. Rapamycin is a naturally occurring 
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macrolide antibiotic, with immunosuppressant, anti-proliferative, anti-migratory 
and anti-vascular smooth muscle cell properties. It is produced by the 
actinomycete Streptomyces hygroscopicus, found on Eastern Island, and is a 
cell cycle inhibitor that arrests the cell at the end of the G1 cell cycle. The 
Sirolimus eluting stent has been followed by the Paclitaxel-eluting stent, 
Paclitaxel being another anti-proliferatve agent. Paclitaxel was originally 
isolated from the bark of the Pacific Yew and exerts its anti-proliferative 
effects through microtubule stabilisation - shifting the balance of microtubule 
eqUilibrium towards assembly, leading to reduced proliferation, migration and 
Signal transduction. The recently published TAXUS IV trial confirmed that 
Paclitaxelleads to equally impressive clinical results as Sirolimus [78]. These 
results have seen drug-eluting stents proclaimed by many as a great 
breakthrough for PCI with restenosis now solved, but others heed caution. 
One potential problem with drug eluting stents is that the biological effect is 
only seen where the drug is in contact with the arterial wall. 
Both of the available agents thus far have anti-proliferative actions, and their 
Use in unstable patients with acute coronary syndromes is still unclear. It may 
be that these 'inflammatory' patients require a different approach. In view of 
this, a role for anti-inflammatory agents has been postulated. 
Dexamethasone is a glucocorticoid with predominantly anti-inflammatory 
effects. Clinical trials with the dexamethasone eluting stent seem promising 
with a 3.3% target lesion revascularisation (TLR), which is comparable to that 
seen with Sirolimus and Paclitaxel, although patient numbers are small and 
further studies are ongoing [79J. 
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The initial results with drug eluting stents are impressive, but longer term 
follow-up is needed and may reveal effects that are less permanent than 
anticipated. No one single process is responsible for restenosis and, 
therefore, it may be that different approaches, including both local and 
systemic delivery of different agents, are necessary for different lesions or 
patient subtypes. 
Advantages of drug-eluting stents are that they provide locally delivered drug 
with no systemic side effects. Drugs can be delivered over a defined period of 
time and the kinetics accurately determined to augment vascular healing. 
Disadvantages are that the drugs can only be delivered for a defined period of 
time and due to physical limitations of the stent, only a finite amount of drug 
can be delivered. Economic concerns include their high price. If a systemic 
agent can be developed that inhibits restenosis, the use of oral agents in 
combination with bare metal stents may offer a cheaper and more effective 
means of dealing with restenosis. 
1.6 Treatment delivery 
1.6.1 Systemic versus local therapy 
Since PTCA became widespread in the 1970s, attempts have been made to 
combat restenosis. Initial strategies concentrated on systemic drug therapy 
using numerous antiplatelet and anticoagulant drugs, with disappointing 
results. Following this, the role of calcium antagonists, omega 3 fatty acids, 
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steroids and various antiproliferative agents were studied [80]. Small initial 
studies showed promise. However, results were not corroborated in larger 
clinical trials. An example of this is the Prevention of REStenosis with 
Tranilast and its Outcomes (PRESTO) trial [81]. Tranilast is an antiallergy 
drug that has inhibitory effects on cytokines, TGFr3 and PDGF. In PRESTO, 
11,500 patients were randomised to receive either systemic Tranilast or 
placebo. Despite promising earlier small-scale studies, the results were 
negative. The main reason cited for the negative results seen with systemic 
therapy was the failure to achieve high drug levels at the angioplasty site. 
This was supported by animal studies where efficacy was only seen when 
high drug dosages were used. It was these disappointing results that led to 
the development of local drug delivery systems. However, not all of these 
have been successful. Early experience with the antiproliferative agent 
Actinomycin D was disappointing because of a high restenosis rate and poor 
long-term outcome. It therefore seems that both the mode of delivery and the 
drug delivered are of equal importance. It is worth noting that the majority of 
clinical trials investigating the use of systemic therapies were conducted in the 
pre-stent era. There have been positive trials using systemic agents in the 
stent era such as oral Everolimus [82] and oral prednisolone [83]. 
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1.7 Conclusions and future directions 
1.7.1 The future of anti-restenosis therapy 
Atherosclerosis is a chronic inflammatory condition and the majority of the 
clinical manifestations of the disease are the direct result of acute on chronic 
inflammatory states. Restenosis following PCI is similar to this in that the 
procedures performed induce local and systemic inflammation, resulting in 
leukocyte infiltration, cellular proliferation and ultimately neointima formation. 
Drug-eluting stents have reduced the incidence of restenosis following PCI, 
and the number of patients requiring re-intervention is now comparable to that 
of CABG [76]. Despite this, there is still uncertainty as to whether the two 
agents in current clinical use, sirolimus and paclitaxel, are sufficient to treat 
the wide variety of lesions found in every day practice. It is also worth 
considering that by concentrating on a different strategy, for example, an anti-
inflammatory rather than an anti-proliferative one, the rate of restenosis may 
be reduced even further. 
1.8 Aims of this thesis 
The hypothesis behind this work was that inflammation plays a crucial role in 
the vessel wall response to injury and stenting and that Inter/eukin-1 is central 
to this inflammatory response. Since IL-1 signalling via the IL-1 R1 receptor is 
a crucial determinant of the arterial response to injury, blocking this with either 
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IL-1 ra or the type" receptor, could modify the response to injury. The aims of 
this thesis, therefore, was to: 
Determine whether the human type" IL-1 receptor could be used as an 
inhibitor of porcine IL-1 using SPR; Establish that IL-1 signalling through the 
type 1 IL-1 receptor was a determinant of the vessel wall response to injury; 
Determine the effect of inhibiting IL-1 signalling in a model of oversized 
balloon angioplasty and coronary stenting in the pig; Quantify differences in 
IL-1 mRNAs in the vessel wall following injury. 
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CHAPTER 2 
HUMAN IL-1 TYPE IIINTERLEUKIN-1 RECEPTOR AS AN INHIBITOR OF 
PORCINE IL-1 
2.1 INTRODUCTION 
2.1.1 Possible inhibitors of Interleukin-1 signalling 
In order to determine whether inhibition of IL-1 action prevents restenosis, 
initial experiments concentrated on finding a molecule or compound that could 
be used in the porcine model of experimental injury. The aim of any anti IL-1 
strategy would be to prevent IL-1 binding to its surface signalling receptor. 
Possible naturally occurring inhibitors of IL-1 include Interleukin-1 receptor 
antagonist (IL-1 ra) and the soluble forms of the IL-1 receptors. The IL-1 
receptors as potential inhibitors were considered first. 
The IL-1 Type 1 receptor (IL-1 RI) has been used as an inhibitor of IL-1 in 
several studies. In a rat model of arthritis, local instillation of IL-1 RI reduced 
jOint swelling and tissue destruction [84]. In a model of experimental 
encephalitis, s1L-1 RI reduced the severity of the disease [85]. However, there 
is some evidence that s1L-1 RI may be ineffective in human disease. A phase-
1 trial of s1L-1 RI was conducted in patients with acute myeloid leukaemia. 
The drug was well tolerated but there was no clinical response to treatment 
and serum levels of IL-1 p remained unchanged [86]. The same was true 
58 
when s1L-1 RI was given to patients with rheumatoid arthritis. There was no 
improvement in clinical outcome [87]. The reason for the lack of effect of slL-
1 RI is thought to be because the s1L-1 RI binds IL-1 ra with the greatest affinity 
(Le. greater affinity than with which it binds IL-1 a or IL-1 P) therefore, s1L-1 RI 
binds endogenous IL-1 ra in preference to IL-1 causing a reduction in its 
biological function [88]. 
IL-1 RII can also be considered as a potential agent for IL-1 inhibition. There 
are three different mechanisms through which IL-1 RII acts as an inhibitor of 
IL-1 that all involve reduction in ligand binding to the membrane bound type-1 
receptor. The first is based on cell-surface bound IL-1 II, which fails to trigger 
IL-1 signalling following ligand binding. This therefore acts as an inhibitor of 
IL-1 by competing with the IL-1 RI for binding of the IL-1 agonists. The second 
mechanism is based on the soluble extracellular form of IL-1 RII (sIL-1 RII), 
which is released from the cell surface (due to protease activity) and binds IL-
1 (thereby preventing it from binding to the type-1 receptor). Again, this 
receptor form produces no signal and therefore elicits no biological response. 
The binding of IL-P to s1L-1 RII is effectively irreversible because of its long 
dissociation rate (>2h) [89]. The third mechanism involves the accessory 
protein (IL-1 RAcP). Following binding of IL-1, the IL-1 RII recruits the IL-1 
RAcp into its non-functioning complex thereby preventing it from binding to 
and forming a signalling complex with IL-1 RI [90]. Using s1L-1 RII as an 
inhibitor of IL-1 is thus analogous to using soluble antibodies against IL-1. 
Unlike IL-1 RI, IL-1 RII binds IL-1 with greater affinity than it binds IL-1 ra. The 
efficacy of IL-1 RII as an inhibitor of IL-1 has been confirmed using gene 
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transfer experiments. These have shown that in chondrocytes, both the slL-
1 RII and IL-1 ra are better inhibitors of IL-1 than s1L-1 RI and are both of 
approximately equal potency. 
An obvious target for IL-1 inhibition therefore was s1L-1 RII and initial work 
concentrated on its use. To determine whether human s1L-1 RII could be used 
as an inhibitor of porcine IL-1 in an experimental injury model, it was 
necessary to determine whether the human receptor would bind porcine IL-1. 
This was done using BIAcore methods where the optical phenomenon of 
surface plasmon resonance was used to detect refractive index changes 
(caused by ligand binding) in a surface layer of a gold foil-coated slide, 
illuminated by monochromic light (A. = 760nm). 
2.1.2 Surface plasmon resonance 
All molecules react with each other, through specific interactions and 
bindings. In order to determine whether a particular inhibitor will be of use in 
any given system, it is first necessary to determine whether the inhibitor will 
interact with its target molecule (protein). One in vitro technique that can be 
used to investigate bimolecular interactions between proteins is surface 
plasmon resonance (SPR) [91]. It has been known for some time that 
electrons can move freely through metal. At a metal-medium interface 
however, dipole excitations cause the propagation of electron waves called 
surface plasmon waves (SPW). The BIAcore instrument is based on this 
optical phenomenon. The SPR optical unit consists of a source of light that 
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passes through a prism and strikes the surface of a flow cell such that the 
angle of the beam is totally reflected (Figure 2). When this occurs, the 
electromagnetic component of the beam propagates into the aqueous layer 
and interacts with mobile electrons in the gold film at the surface of the glass. 
At a particular wavelength and incident angle, a SPW of excited electrons (the 
plasmon resonance) is produced at the gold layer and is detected by the 
optical unit as reduced intensity of the reflected light beam (Figure 2). The 
SPR angle is sensitive to the composition of the layer at the gold surface. A 
baseline SPR angle is first calculated following binding of the ligand to the 
dextran matrix within the BIAcore chip. When protein flows across the chip, 
ligand binding causes an increase in the refractive index at the surface of the 
chip, thereby changing the SPR angle and the detection on the optical unit. 
The BIAcore technology reports the change in SPR angle as resonance units 
(RU), where 1000 RU corresponds to a change of -0.1°. For most proteins, 
this equates to binding of - 1 ng/mm2 of protein. 
SPR has already been used to study the binding of human IL-1 cr, IL-1 p and 
IL-1 ra to human soluble IL-1 receptors [89]. This work confirms that SPR is a 
good technique for determining cytokine-receptor ligand binding and has been 
shown to be effective for IL-1. 
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Figure 2 SPR optical unit and a sensor chip 
The protein molecules (circles) bind to the immobilised ligand (diamonds) that 
is linked to the dextran matrix. The SPR angle (T1 before ligand binding and 
T2 after binding) defines the position of the reduced-intensity beam. 
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2.1.3 Aim of this study 
The aim of this section of work was to determine whether human IL-1 RII could 
bind porcine IL-1 and therefore be used as an inhibitor of IL-1 in a porcine 
model of experimental injury. 
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2.2 MATERIALS AND METHODS 
All chemicals for were from Sigma (Poole, Dorset, UK), apart from the 
recombinant cytokines, which were from R&D Systems (Oxford, UK). All 
chemicals needed for the BIAcore system were obtained directly from 
BIAcore, UK. 
The sensor chip (BIAcore, UK) consisted of Carboxymethyl-dextran linked to 
a layer of gold. This provided an interaction layer, which was approximately 
1 OOnm thick. One of the interacting molecules, in this case the human soluble 
type 2 IL-1 receptor (sIL-1 RII), was bound to the gold-layer on the chip in 
order to create a biospecific recognition site. In order to achieve this binding, 
the chip was docked into the BIAcore machine with the gold-dextran layer 
forming one side of the flow cell through which the solutions run. The s1L-111 
was covalently bound to the chip surface (via functional amine groups) to the 
dextran-carboxyl groups. This process is known as amine coupling. Once 
the ligand was bound, the excess NHS groups were blocked by a pulsed 
wave of ethanolamine (Biacore, UK). Any change in refractive index and 
therefore response units (RU) was due to binding of the ligand to the 
immobilised receptor. Further details of the type of BIAcore instrument 
(BIACORE 3000) used are given in the manufacturers handbook [92]. 
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2.2.1 Receptor immobilisation to the BIAcore chip surface 
All cytokines used for the BIAcore work were ordered 'carrier-free' to ensure 
that non-specific binding to the sensor chip by carrier proteins was avoided. 
The s1L-1 RII was covalently immobilised to a hydrogel chip (BIAcore, UK), 
using N-hydroxysuccinimide (NHS)-based chemistry, i.e., via lysine E-amino 
groups. Each chip had 4 flow cells to which ligand could be bound. The flow 
cells were paired up, with one used for ligand binding (the active cell), and the 
other as a control. Flow cells 2 and 4 were used for ligand binding and 1 and 
3 as their respective controls. The chip surface was activated with a 7min 
pulse (3SIJL at SIJUmin) of a mixture of SOmM NHS and 200mM 
ethylcarbodiimide (EDC) premixed before injection. This was immediately 
followed by an injection of 1 OOIJL (at SIJL Imin) of 10mM sodium acetate, pH 
S.O (BIAcore, UK), containing 40IJg/ml s1L-1 RII over flow cells 2 and 4. This 
step was omitted in the preparation of flow cells 1 and 3. Excess untreated 
NHS groups were then blocked with a pulse of 1.0M ethanolamine 
hydrochloride, pH 8.S (3SIJI at SlJl/min). All reactions during the covalent 
coupling were performed with the standard BIAcore immobilisation buffer, 
10mM sodium acetate, pH S.O. 
2.2.2 Ligand binding to s1L-1 RII on the chip surface 
These experiments were performed to determine whether human siL 1 RII 
would bind porcine IL-1 ligands. Of all the human IL-1 ligands, human IL-1 p 
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binds to the human type II receptor with the greatest affinity [89]. The IL-1 ~ 
cytokine was therefore used as a positive control in the following experiments. 
For measurement of direct ligand binding to immobilised slL 1 RII, 50IJL of 
each ligand was flowed over the chip at 5lJUmin. Human IL-1 ~ (R&D 
Systems, Oxford, UK) was flowed over flow-cell 2 of the chip at a 
concentration of 2.94IJM, (IL-1 ~ has previously been shown to bind to the type 
2 receptor at a concentration of 3nM [89]). Porcine IL-1J3 and IL-1a were both 
used at 5.81JM and flowed over flow-cell 4 of the chip in the same way as the 
human ligand. All experiments were performed using the standard BIAcore 
running buffer, 0.15M HEPES-buffered saline, 3.4mM EDTA and 0.05% v/v 
Tween 20, pH 7.4. 
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2.3 RESULTS 
2.3.1 Immobilisation of the type II receptor 
Figure 3a and 3b show coupling of the s1L-1 RII to flow cells 2 and 4 of the 
sensor chip. The horizontal lines on the chart represent the response units 
(RU) generated (as determined by the change in refractive index) by amine 
coupling of human s1L-1 RII to the chip. Point A represents the initial injection 
of the NHS/EDC mixture over the chip. Point B indicates the start of injection 
of the s1L-1 RII. There is a gradual increase in RU until point C when injection 
of the s1L-1 RII stops and ethanolamine is flowed over the chip instead. This 
blocks excess untreated NHS groups and so the final change in RU due to 
binding of s1L-111 receptor can be seen at point D. There is a change of 8786 
response units (RU) after immobilization of the receptor to flow cell 2 and 
8596 response units after its immobilization to flow cell 4. It is known that 
binding of 1 ng/mm2 of a protein results in a change in RU of approximately 
1000 [92]. Therefore, approximately 8.79ng/mm2 of s1L-111 receptor is bound 
to flow cell 2 and 8.60ng/mm2 to flow cell 4. 
Figures 4a and 4b demonstrate the change in RU after amine coupling of flow 
cells 1 and 3, the control flow cells. The control flow cells are subjected to 
exactly the same conditions as the active cells (see Figures 3a and 3b) except 
that no s1L-1 RII is flowed over the chip. There is a change of only 179 RU in 
flow cell 1 and 137RU in flow cell 3. 
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Figure 3 1m mobilisation of s1L-1 RII to (a) flow cell 2 and (b) flow cell 
4 of the sensor chip 
A: Injection 35J,JL of EDC/NHS coupling mixture 
B: Injection of 100J,JL of human s1L-1 RII 
C: Injection of 35J,JL of ethanolamine 
D: RU due to binding of s1L-1 RII receptor 
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2.3.2 Ligand binding 
Ligand binding to s1L-1 RII is shown in Figures 5 - 7 (pages 71 - 73). Figure 5 
shows the response to human IL-1 ~ in flow cell 2. The pink line represents 
the flow cell that has s1L-1 RII bound and the blue line the control cell. Human 
IL-1 ~ is flowed over the chip from 1500 seconds. There is a clear increase in 
RU in response to the human IL-1 ~ and after 5 minutes; there has been a 
change of 960RU. This is equivalent to 0.96ng/mm2 of human IL-1 ~ bound to 
the chip. This figure shows that the total RU does not return to baseline, 
indicating that some IL-1 ~ remains bound. For this reason, flow-cell 4, a 
separate flow cell, was used to investigate binding of the porcine ligands. In 
the control, i.e. flow-cell 1, there is change of only 22RU in response to 
human IL-1~, indicating that there is no real binding. Figure 6 shows the 
response to porcine IL-1 u. There is a change of 18 RU in the active cell and 
o RU in the control cell, implying that under the conditions used; porcine IL-1a 
does not bind to human s1L-1 RII. The same is true of porcine IL-1~, as shown 
in Figure 7. The injection commenced at 220 seconds and lasted for 5 mins. 
Flow-cell 4 actually shows a decrease of 25 RU. The most likely explanation 
for this is a disparity in pH when preparing and using the chip. In the 
immobilisation step, the pH of the solutions used is 5.0. When attempting to 
bind the ligands, solutions of pH 7.4 are used. It is likely the decrease in RU 
is due to some elution of the s1L-1 RII from the chip in response to change in 
pH. 
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control flow cell 
, 
3000 
The pink line shows the binding of human IL-1 P binds to the immobilised slL-
1 RII receptor in flow cell 2 and the blue line the corresponding binding to the 
control cell. Note: The increase in RU 5 min after binding of human IL-1 P is 
960RU. This is equivalent to O.96ng/mm2 of human IL-1 P bound to the chip. 
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The green line shows the binding of porcine IL-1 p to flow cell 4 (with s1L-1 RII 
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was commenced at 220 seconds and lasted for 5 mins. Note: A change of 0 
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2.4 DISCUSSION 
2.4.1 Summary of findings 
These experiments were performed to determine whether the human s1L-1 RII 
could be used to inhibit IL-1, in a porcine model of coronary artery 
experimental injury. The results presented here show that human s1L-1 RII 
does not bind porcine IL-1 and therefore cannot be used as an inhibitor of IL-1 
activity in this model. 
2.4.2 Why does porcine IL·1 not bind to s1L·1 RII? 
Surface plasmon resonance was used to determine whether human s1L-1 RII 
would bind porcine IL-1. Human s1L-1 RII was captured on the surface of a 
sensor chip in a BIAcore instrument and the association kinetics of human IL-
1~, porcine IL-1 ex and porcine IL-1 ~ ligands measured. The conditions were 
chosen to replicate those that had already been used to determine the binding 
kinetics of human IL-1 to human s1L-1 RII and these were verified by the 
positive control, human IL-1~, which bound to the immobilised s1L-1 RII as 
expected [89]. It can be seen from the data presented (section 2.3.2) that 
under the conditions tested and the concentrations used, neither porcine IL-1a 
nor porcine IL-1 ~ bound to the human s1L-1 RII. 
Several possible explanations for these results exist. Firstly, the homology 
between human IL-1~ and porcine IL-1~ is only 74% [93]. Ligand-receptor 
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interactions are highly specific and the differences in amino-acid sequence 
between the porcine and human ligands may prevent receptor-ligand complex 
formation. Secondly, direct binding may be limited by transport of the ligand 
to the chip surface. This seems unlikely as good binding was achieved 
between the human ligand and immobilised receptor implying the ligands 
were reaching the immobilised receptor and in contact with it long enough to 
bind. Thirdly, the carboxylated dextran matrix at neutral pH has a negative 
charge and may exert an effect on the binding affinity of the receptor. 
Fourthly, it is conceivable that binding of the ligands occurred but the off-rate 
of the ligand was so fast as to be undetectable by the BIAcore instrument. 
This seems highly unlikely due to the sensitivity of the machine and even if 
that were the case, it would still mean that the human IL-1 RII could not be 
used as an efficient inhibitor in a porcine model. 
2.5 Conclusions and future directions 
Under the conditions tested in this thesis, human s1L-1 RII does not bind 
porcine IL-1 ex or porcine IL-1 p. In order to test the hypothesis that IL-1 is a 
crucial determinant in the coronary artery response to injury and intracoronary 
stenting, an inhibitor that can be tested in an animal model of experimental 
injury is required. There is another commercially available inhibitor of IL-1, IL-
1 ra, that has already been tested in an animal model and was found to be 
effective [94]. IL-1 ra is commercially available (Anakinra; Amgen) and is 
already in clinical use for the treatment of rheumatoid arthritis [95]. 
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Previous work had shown that human IL-1 ra is inhibitory in the mouse [35] 
and preliminary work in our laboratory, using an in vitro radioligand binding 
assay had determined it was inhibitory to IL-1 signalling in the pig (data not 
shown). 
In order to take this work forward, it was decided to concentrate on inhibition 
of porcine IL-1 using human IL-1 ra to determine whether the coronary artery 
response to injury could be modified. 
76 
CHAPTER 3 
DELIVERY AND PHARMACOKINETICS OF HUMAN IL·1 RA IN PIGS 
3.1 INTRODUCTION 
3.1.1 IL·1 ra as an inhibitor of IL·1 
As discussed in 1.2.5, IL-1 ra is a naturally occurring antagonist of IL-1. It has 
been used with good effect in the treatment of rheumatoid arthritis in humans 
[40] and is well tolerated at high doses with few side effects. It acts as a 
competitive inhibitor by binding preferentially to the type 1 IL-1 receptor 
thereby preventing the up-regulation of down-stream inflammatory cytokines 
such as IL-6 and IL-8. IL-1 ra is an acute phase protein that is produced in a 
pattern that immediately follows IL-1 production. Mice that lack IL-1 ra 
spontaneously develop arthritis [96]. This suggests that it is the balance 
between IL-1 and IL-1 ra that is crucial in disease prevention. It follows that 
the ratio of IL-1 to IL-1 ra is imbalanced either because of excess IL 1 
production or reduced IL-1 ra production. The onset of inflammatory 
conditions leads to a rapid induction of s1L-1 ra synthesis by the liver [97]. IL-
1 ra is needed in 1 DO-fold excess over IL-1 in order to exert its effects [20]. 
Given the short half-life of IL-1 ra, prolonged administration regimes are 
required. 
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3.1.2 Human IL-1 ra and inhibition of porcine IL-1 
The homology between human and porcine IL-1 ra is 80%. Preliminary work 
in our laboratory using an in vitro bioassay determined that human IL-1 ra was 
an effective inhibitor of porcine IL-1 and therefore had potential to be used in 
a porcine model of experimental injury. This was confirmed by in vivo data 
available from our collaborators at Amgen. 
3.1.3 Dosing regimen for IL-1 ra 
Numerous studies have used different doses of IL-1 ra to inhibit IL-1. Elhage 
et al used IL-1 ra in a mouse model of fatty streak formation at a dose of 
25mg/kg/24h [35]. In a study by Bendele et al on the efficacy of IL-1 ra in a rat 
model of rheumatoid arthritis, the dose studied was 5mg/kg/24h [94]. In 
human studies, doses as high as 3400mg/24h have been used [42]. 
Interestingly, the doses used in individual studies span a wide range and each 
seems to be effective. It has been reported that IL-1 ra needs to be circulating 
in 100-fold excess to IL-1 levels to exert its effects [20]. The work presented 
in this thesis used an initial dose of 2mg/kg/24h. This was based on a 
recommendation from Amgen who provided the drug. 
3.1.4 Mode of delivery of IL-1 ra 
IL-1 ra has a short half-life of 3 - 6 hours [98]. Whatever the dosage, in order 
for IL-1 ra to have a sustained effect it must be given by a continuous infusion. 
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The operating paradigm is such that the IL-1 ra is circulating at high levels at 
the time of injury. There are two possible methods of giving a continuous 
infusion, via an intravenous or subcutaneous route. The advantages of giving 
a continuous intravenous infusion are that the serum levels are often more 
predictable and high circulating levels can be rapidly achieved. Against this 
route, although continuous intravenous administration is technically feasible 
and possible, in large animals, it is fraught with difficulty. Any intravenous 
access will have to be central for a prolonged infusion. This means that an 
intravenous line will need to be placed into either the internal jugular or 
subclavian artery and then to administer the infusion, the line will have to be 
connected to an external syringe driver or similar device and placed on the 
animal. This necessitates the animal wearing a 'coat' with pockets to house 
the device, which is cumbersome, heavy and uncomfortable for the animal. 
Once the animals have fully recovered from their anaesthetic they are 
returned to their pen where they live with other pigs until death (in this case up 
to 28-days). Being naturally inquisitive animals, in the experience of our 
laboratory, they often chew anything out of the ordinary including intravenous 
lines and syringe drivers. Consequently, a central line could become 
displaced over night leaving the animal without its infusion for anything up to 
24 hours at a weekend. As the half-life of IL-1 ra is much shorter than this (3 -
6 hours), an animal could potentially be without drug for a critical amount of 
time thereby biasing the experiment and its results. 
The advantages of subcutaneous administration are that mini-osmotic pumps 
are available that can deliver a fixed rate of drug for a fixed amount of time, 
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thereby allowing predictable infusion times (see 3.2.5). These pumps are 
placed in a subcutaneous pocket (in the case of a pig in the groin crease of 
the animal). Insertion therefore involves a single operation and the animal is 
left with a wound. If the pumps need replacing again, a simple quick 
operation is all that is needed. There is no need for an external driver to 
deliver the drug. Against subcutaneous administration, serum levels can be 
erratic and unpredictable and when osmotic pumps are used, there have been 
occasional reports of swelling around the pumps. 
Given the above, it was decided to use subcutaneous mini-osmotic pumps to 
deliver a continuous infusion of drug, with an intravenous bolus at the time of . 
injury if necessary to ensure initial high circulating levels. 
3.1.5 Aims of this study 
The aim of this section of the research was to determine the optimal delivery 
method and consequently, the pharmacokinetics of human IL-1 ra delivery to a 
pig. 
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3.2 MATERIALS AND METHODS 
3.2.1 Yorkshire White pigs 
In vivo work was performed on normo-lipemic, domestic, crossbred Yorkshire 
White pigs. They were of either sex, obtained from a Home Office designated 
supplier and weighed approximately 20kg. 
3.2.2 Animal husbandry 
Animals were housed at the University of Sheffield in appropriately sized 
pens. They were fed unmodified pelleted chow and had free access to water. 
Animals were examined daily to ensure well-being. Diseased animals were 
not used for this study and any complications such as infection were dealt 
with using standard veterinary procedures. 
3.2.3 Legal considerations 
Animal experiments were performed under an appropriate UK Home Office 
Project Licence (Dr J Gunn, 50/01335) and Personal Licence (Dr A Morton, 
40/6898). All experiments were performed in a Home Office designated 
establishment (Field Laboratory, University of Sheffield). 
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3.2.4 Cytokines 
The human IL-1 receptor antagonist (IL-1 ra) used for the following work was a 
gift from Dr C. Toombs, Amgen, CA, USA. All other cytokines were 
purchased from R&D systems. The initial dose of IL-1 ra used in this study 
(2mg/kg/24h) was that recommended by Dr C. Toombs. The dose used was 
based on both animal and clinical data Amgen had collected on the use of IL-
1 ra in rheumatoid arthritis. 
3.2.5 Subcutaneous osmotic pumps 
In order to give a continuous infusion of IL-1 ra, subcutaneous osmotic 
minipumps were used. These are miniature, implantable pumps that 
continuously deliver the agent of choice at a controlled rate for a set time, 
without the need for external connectors or frequent animal handling. Alzet 
pumps work by osmotic displacement. The empty reservoir within the core of 
the pump is filled with IL-1 ra solution, using a blunt ended filling tube. The 
chamber surrounding the reservoir (but isolated from it by an impermeable 
layer) contains a high concentration of salt solution. Due to this high 
concentration of salt, water enters the pumps through its outer surface, which 
is a semi-permeable layer. The entry of water increases the volume of salt in 
the chamber, causing compression of the flexible reservoir and delivery of the 
IL-1 ra via the exit port. To ensure that mean rate of delivery; pump-to-pump 
consistency; and the accuracy of pumping over time is consistent, the supplier 
calibrates the pumps. 
82 
3.2.6 Filli~g and priming of the osmotic pumps 
Osmotic pumps were purchased from Charles River UK Ltd. Kent, UK. Each 
2ml2 pump held 2ml of solution and released for 14d at a flow rate of 51J1/hr. 
Three pumps were inserted into each animal in order to achieve the required 
dosage. The volume of solution loaded into the pumps was calculated 
according to a method supplied by Charles River Ltd. First, the empty pump 
together with its flow moderator was weighed. A blunt-tipped filling tube was 
then used to fill the pump with IL-1 ra. A dose of 2mg/kg/24h was delivered to 
the animal (as advised by Amgen). Once full, the excess solution was wiped 
off and the flow moderator inserted until the cap was flush with the top of the 
pump. The pump was then re-weighed. The difference in weights gave the 
net weight of solution loaded. For aqueous solutions, the weight in milligrams 
(mg) is approximately the same as the volume in microlitres (IJI). The fill 
volume for all pumps was >90% of the reservoir volume specified on the 
specifications sticker attached to the information sheet sent with the pumps. 
This ensured that sufficient solution was loaded. Once full, the pumps were 
primed for use in a beaker of normal saline at 37°C overnight. 
3.2.7 Implantation of subcutaneous mini osmotic pumps 
Prior to pump implantation, pigs were sedated with an intramuscular injection 
of azaperone (12mg/kg, Janssen Animal Health). Anaesthesia was induced 
by intravenous propofol, (4mg/kg, Zeneca Pharmaceuticals) and maintained 
by inhaled isoflurane (4-6%) in oxygen (1 Umin) via endotracheal tube. 
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Animals were positioned supine on the table with their legs secured, the groin 
crease was cleaned with iodine and sterile towels used to cover the cleaned 
area. An incision approximately 1.5 inches long was made in the groin 
crease. A pocket for the pumps was created subcutaneously by blunt 
dissection. The filled pumps were inserted into the pocket, delivery portal first 
(to minimise interaction between the compound delivered and the healing of 
the incision). The wound was closed with 2.0 Vicryl sutures and the animals 
allowed to recover. 
3.2.8 Pharmacokinetics of IL·1 ra 
-. 
Initially the release profile of the IL-1 ra from the osmotic pumps was 
determined. It was important to know the circulating levels of IL-1 ra after 
pump implantation and how long levels were maintained for in order to ensure 
consistency for subsequent procedures. 
3.2.9 Pharmacokinetics of subcutaneous IL·1 ra release from 
Miniosmotic pumps 
Subcutaneous mini osmotic pumps were inserted as 2.3.2. Blood (2m/) was 
collected into heparinised syringes at the following time points: pre-procedure; 
at implantation; 10min; 20min; 30min; 1 h; 2h; 4h; 8h; 24h; 48h; 72h; 7d; 10d; 
14d; 17d; 23d and 28d. The blood was immediately centrifuged at 2000rpm 
for 3min; serum was extracted, aliquoted (200IJL per sample) and stored at -
80°C until use. 
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3.2.10 Pharmacokinetics of intravenous bolus administration 
This experiment was carried out as above (2.3.1 ) except that before the 
pumps were inserted, intravenous (iv) access was gained in either an ear vein 
or the femoral vein and at the time of pump implantation, an iv bolus of IL-1 ra 
at a dose of O.5mg/kg was given. Blood was sampled at the following time 
points: pre-procedure; at implantation; 15min; 30min; 45min; 1 h; 1 h15min; 
1 h30min; 1 h45min; 2h; 3h; 4h; 5h; 6h; 7h; 8h; 9h; 10h; 24h and 48h. 
3.2.11 Determination of serum levels of IL·1 ra after administration 
Serum samples were collected as 2.4.1, stored at -80°C and shipped on dry 
ice to Amgen Inc. for analysis. 
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3.3 RESULTS 
3.3.1 Pharmacokinetics of inhibitor release from mini osmotic pumps· 
subcutaneous infusion 
The pharmacokinetics of IL-1 ra release from the mini osmotic pumps are 
shown in Figures 8a and 8b. Each time-point represents the mean value from 
serum samples taken from 3 separate pigs. There is a peak elution at 8 
hours. After this a steady state of release is achieved with serum levels of 
150 - 250ng/ml. This level is maintained for 18 days after which, the serum 
levels decrease. By 23 days, no more IL-1 ra is eluted. 
3.3.2 Intravenous bolus administration 
To ensure that IL-1 ra is circulating at the time of injury, an intravenous (iv) 
bolus of IL-1 ra (0.5mg/kg) was given at the time of pump implantation. In 
Figure 9, each time-point represents the mean value from serum samples 
taken from 2 separate pigs. Peak levels occurs at time-point 0 i.e. 
immediately after injection. After this, a steady state of release is achieved 
with serum levels of 150 - 250 ng/ml. 
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Serum concentration of IL·1 ra following implantation of 
subcutaneous pumps that release IL·1 ra at 2mg/kg/24h 
(a) shows the first 24h of elution with a peak of 680ng/ml falling to steady 
state; (b) shows steady state levels up to 18 days with no elution after 23 days 
(n=3). 
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Figure 9 Serum concentration of IL-1 ra after administration of an 
intravenous bolus (dose O.5mg/kg) (n=2) 
Note a rapid peak of elution of IL-1 ra (2.9J..19/ml) immediately post bolus. 
Steady state levels are maintained over the subsequent Bh. 
88 
3.3.3 Pharmacokinetics of inhibitor release from iv bolus and mini 
osmotic pumps 
The combined data from intravenous bolus and insertion of subcutaneous 
mini osmotic pumps are shown in figure 10. It can be seen, that peak elution 
of IL-1 ra occurs immediately after the intravenous bolus has been given and, 
by 1 hour, the serum concentration has reached steady state with serum 
levels of 150 - 250 ng/ml. This level is maintained for 18 days after which 
time the level decreases to below 100ng/ml. By 23 days, there is no elution of 
IL-1 ra from the miniosmotic pumps. 
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Figure 10 Serum concentration of IL-1 ra after iv bolus and 
subcutaneous mini osmotic pump insertion 
Note: an initial high peak (Fig 9) occurs followed by maintenance of steady 
state levels for 14-days. Levels fall below 100ng/ml at 18 days and to 0 by 23 
days. 
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3.4 DISCUSSION 
3.4.1 Summary of findings 
The pharmacokinetic data for the administration of human Interleukin-1 
receptor antagonist to the domestic pig show that both methods of 
administration (intravenous and subcutaneous mini pump) cause an initial 
peak of IL-1 ra in the plasma, after which time levels rapidly decrease to a 
steady state level of 150 - 250ng/ml. This suggests that after administration, 
IL-1 ra is compartmentalised within the body, leaving a steady level to 
circulate. 
3.4.2 Delivery strategy 
In chronic conditions, therapy needs to be sustained for an extended period 
and large doses may be necessary. In the case of IL-1 ra, which has a short 
half-life, the route of administration of IL-1 ra will be critical to its success as a 
commercially available drug. In the treatment of patients with rheumatoid 
arthritis, large amounts of recombinant protein are needed [40]. Various slow 
release formations are being investigated but a pump device still seems to be 
the most likely method of administration. Pumps have the advantage over . 
subcutaneous injection that they provide a uniform release of drug. However, 
a question exists over protein lability under physiological conditions. The 
research reported here show that a steady state of drug elution can be 
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obtained using miniosmotic pumps. The efficacy of the delivered IL-1 ra still 
needs to be established. 
3.4.3 Steady state levels 
According to the manufacturers instructions, the pumps elute for 14-days. It 
can be seen from the serum levels obtained that the pumps actually release 
drug for up to 18-days. After this time the levels of serum IL-1 fall to below 
100ng/ml and by 23-days, levels are undetectable. The reasons for 
prolonged administration are unclear. As the half-life of IL-1 ra is 3-6 hours, 
this continued release must be either from the pumps that are left in situ or 
-
from a slow release compartment. The level of detectable IL-1 ra falls to 
below 100ng/ml after 21-days and it is likely that the effect of the inhibitor on 
IL-1 is negligible after this time (although this has not been formally tested). 
3.4.4 The importance of an intravenous bolus 
It is reported that high levels of IL-1 ra circulating at the time of injury are 
required, since the initial events in the vessel wall response to injury occur 
early on and rapidly [3]. As already discussed (1.2.7), work from our group 
has shown that IL-1 ~ is up-regulated in the porcine vessel wall as early as 6 -
hours following PTCA [31]. Given that a 100-fold excess of IL-1ra is required 
to inhibit IL-1, a subcutaneous infusion started at the same time as the 
experimental injury was performed may not provide sufficient amounts of IL-
1 ra for complete IL-1 inhibition. To ensure high circulating levels at the time 
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of injury, either the pumps would have to be implanted a day before the injury 
or an intravenous bolus delivered. To implant the pumps a day before vessel 
injury or stenting would necessitate the animal undergoing another procedure 
and therefore another anaesthetic. With this in mind, an intravenous bolus 
was chosen since it was easy to administer, involved no added anaesthetic or 
increase in procedure time. 
3.4.5 How much IL·1 ra is enough? 
The amount of circulating IL-1 ra needed to inhibit the inflammatory response 
induced by IL-1 is unknown. Previous work looking at the effect of IL-1 ra on 
rheumatoid arthritis in a rat model found that administration of 5mg/kg/24hr of 
IL-1 ra gave serum levels of 5.51Jg/ml that was sufficient to cause complete 
(90%) suppression of established arthritis [94]. Interestingly, in this study, the 
response in an adjuvant-induced arthritis model was not as dramatic 
highlighting the variability in response seen by different models with identical 
serum levels. The role of antagonising IL-1 in fatty streak formation (the initial 
step in the atherosclerotic process) in apolipoprotein-E deficient mice (a 
standard animal model of atherosclerosis) has also been studied [35]. Here, 
specific antagonism of IL-1 with IL-1 ra was effective in reducing fatty streak 
formation, suggesting a crucial role for IL-1 in the initial step of the 
atherosclerotic process. In this work, administration of 2mg/kg/24h of IL·1 ra 
led to serum levels of 150 - 250 ng/ml for the duration of the infusion. 
Although the serum levels we obtained were lower that that seen in the study 
on rheumatoid arthritis, these levels were remarkably consistent and it would 
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seem that any excess IL-1 ra circulating in the pig model is either 
compartmentalised or rapidly excreted by the kidneys, leaving a maximum of 
250ng/ml available in the serum. It is uncertain whether this serum level is 
high enough to suppress IL-1 activity or if higher levels will be necessary after 
injury. These initial data however, confirm that human IL-1 ra can be 
administered to pigs with no obvious side effects and that human IL-1 ra can 
be detected in pig serum following administration i.e. there is no species 
cross-reactivity with the human IL-1 ra. 
3.5 Conclusions and Future Directions 
Human IL-1 ra administered to pigs as an intravenous bolus (0.5mg/kg) 
followed by a continuous subcutaneous infusion (2mg/kg/24h), gives an initial 
peak followed by a steady state serum concentration of 150 - 250ng/ml. This 
work has shown that human IL-1 ra can be delivered successfully to a pig in 
the manner described above. Serum levels are consistent and reproducible 
between animals implying a working delivery system with predictable 
pharmacokinetics. The next step is to establish whether the serum levels 
obtained are high enough to inhibit porcine IL-1 and therefore inflammation. 
In order to do this, a skin bioassay as a surrogate for the porcine coronary 
artery will be used. 
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CHAPTER 4 
DOSE.RESPONSE ANALYSIS - INHIBITION OF IL·1 INDUCED 
INFLAMMATION IN A PORCINE SKIN MODEL 
4.1 INTRODUCTION 
4.1.1 Skin as a surrogate for the coronary artery 
In order to determine the efficacy of human IL-1 ra as an inhibitor of porcine IL-
1, it was necessary to use a bioassay that allowed a large number of samples 
to be taken from each animal. It was important to determine whether IL-1 ra at 
the dose studied was inhibitory to IL-1 induced inflammation before moving 
onto the model of experimental injury to ensure that the serum level being 
delivered was adequate to abolish an inflammatory response. It follows 
therefore that if the dose of IL-1 ra given were not anti-inflammatory then 
higher doses would be necessary to examine the efficacy of an anti-IL-1 
approach to restenosis. A porcine coronary artery model does not allow 
either varying doses of IL-1 or different time-points to be tested in the same 
animal because each animal can receive only one infusion and in order to 
harvest the artery, the animal must be killed, thereby limiting the information 
obtained from each animal. Also, there is no established model of porcine 
coronary artery inflammation. As an altemative to the coronary artery, a 
model of inflammation in pigskin was used. Advantages of using pigskin 
include similarities between pig and human skin [99] and the ability to study 
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replicate skin-spots within the same animal for several treatments at several 
different time-points. A study by Binns et al [100] used a similar model to . 
examine the importance of E-selectin antagonism on neutrophil infiltration. In 
this model, cytokines were injected intradermally into the ventral-abdominal 
and medial-thigh skin at 24h, 4h, 2h and 45 min before exsanguination. 
Neutrophil accumulation was maximal at 4h pre sacrifice. There was little 
accumulation in unstimulated skin [100]. This skin model would therefore be 
appropriate to establish whether IL-1 ra at the dose studied could inhibit the 
inflammatory reaction induced by intradermallL-1 injection, before moving on 
to study any IL-1 ra effect on restenosis. 
4.1.2 Bioassay for IL·1 ra effects on inflammation in pig skin. 
Changes in the vascular endothelium occur during an inflammatory response 
that allows access of neutrophils and lymphocytes to tissues. Neutrophil 
recruitment to intradermal (id) injections of porcine IL-1 a and IL-1 p was used 
as a bioassay of in vivo IL-1 antagonism by the selected dose of human IL-1 ra 
[100]. Neutrophils constitute approximately half the circulating white cell 
population in most species, including pigs and are characterised by a 
multilobed nucleus and cytoplasmic granules. The primary function of the 
neutrophil is in host defence. Neutrophils therefore accumulate at sites of 
infection and inflammation. Accumulation is a controlled event such that the 
inflammatory responses usually resolve acutely with the efficient removal 
(within days) of the inciting stimulus. If control mechanisms fail and there is 
an over-exuberant response or non-resolving response to injury, then 
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neutrophil accumulation and activation can lead to tissue destruction. Of 
importance to any bioassay is the standard curve, which is used to accurately 
determine the response induced by a particular agent or change in conditions. 
In this case, the standard curve was created using neutrophils extracted from 
pig blood. A large number of peripheral neutrophils can be isolated from each 
animal, thereby providing a simple, reproducible standard for each assay. 
4.1.3 Myeloperoxidase 
Myeloperoxidase (MPO) is a cationic protease that is an abundant component 
of neutrophil azurophil granules. It constitutes 5% of the dry weight of the cell 
and is released when neutrophils are activated [101]. Myeloperoxidase 
(MPO) activity is a direct measure of neutrophil presence and a surrogate 
marker for their infiltration into tissue [102]. Many different assays are 
available that can detect MPO and these can be used to indicate neutrophil 
levels within tissue [102-104]. 
4.1.4 Aim of this study 
The aim of this section of work was to determine whether the circulating 
serum dose of IL-1 ra (150 - 250ng/ml) achieved by an intravenous bolus of 
0.5mg/kg and a continuous subcutaneous infusion of 2mg/kg/24h was 
sufficient to inhibit neutrophilic inflammation induced by intradermallL-1 
injection. 
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4.2 MATERIALS AND METHODS 
4.2.1 Intradermal injection of Interleukin-1 with and with out 
intravenous bolus and continuous subcutaneous infusion of IL-1 ra -
dose response analysis 
The skin assay (discussed in 4.1.2) is a useful model for investigating the 
effects of interleukin-1 in a non-invasive manner. Multiple sites can be used 
and therefore multiple doses and time-points analysed in the same animal. 
Stock solutions of IL-1a and IL-1f3 (both from R&D systems, Oxford, UK) at 
concentrations: 300U; 1000U; 3000U and 10,000U were prepared, using the 
vehicle as a diluent. Pumps were filled and primed with 2mg/kg/24h of IL-1 ra 
as described in section 3.2.6. Pigs were anaesthetised as previously 
described section 3.2.7. If the pig was to receive IL-1 ra, intravenous access 
was gained and a pocket created for pump implantation. The pumps were 
inserted and an intravenous bolus given immediately prior to the first 
intradermal (id) injection. A pre-prepared plan for id injection was made. A 
grid was drawn onto the abdomen of the animal (see Figure 11). Each grid 
had 60 individual points marked in a 12 X 5 formation and each point was 
labe"ed with a number and letter i.e. 5 rows horizontally labe"ed A - E and 12 
rows vertically labe"ed 1 - 12. Each dose and time-point was documented on 
a paper copy of the grid and then at the appropriate time, the id injection given 
in the corresponding point on the abdomen of the animal. Each injection 
consisted of 0.1 ml of porcine IL-1a, porcine IL-1 f3 or saline (used as a 
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Figure 11 Grid markings for intradermal injection sites 
Animals had a 12 X 5 grid drawn onto the ventral abdominal wall as shown. 
Intradermal injections were made over each separate 'dot' and then each 
injection site was circled to depict external limits for subsequent disk removal. 
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control). Intradermal injections were performed at the following time points: 
24hr; 6hr; 4hr; 2hr; 1 hand Oh pre-death [100]. 3 - 5 separate discs of skin 
were injected for each time-point. At time point 0, the pig was killed by lethal 
injection and the skin on the ventral surface of the pig harvested by 
superficially cutting through the skin around the grid and removing the skin 
using sharp and blunt dissection. Once removed, the skin was stretched out 
and nailed to a piece of wood. Each disk of skin was removed using a 
hammer and punch (Footprint Tools, Sheffield, UK) and the disks then either 
placed into formalin for 24h followed by PBS (for histology) or frozen and 
stored in liquid nitrogen for later use. 
From previous experiments in our group after injury [31], IL-1 ~ is expressed in 
pig coronary arteries up to 14d but maximally at day 3. The half-life of IL-1 ra 
in humans after subcutaneous infusion is 3 - 6 hours (data from Amgen). In 
order to determine whether the sc infusion alone would continue to inhibit 
neutrophil recruitment after the effect of the iv bolus had disappeared, in 1 pig, 
sc pumps were inserted and an iv bolus given 3 days prior to any id injections. 
4.2.2 Measurement of myeloperoxidase in skin samples 
The levels of MPO were measured in skin biopsies. The skin sections were 
made into homogenates by a process described in 4.2.4. The MPO 
concentration was determined by a previously described colorimetric-based 
method [103] using ultraviolet spectrophotometry and Labsystems Genesis 
v3.05 software. 
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4.2.3 Preparation of pig neutrophils by Percoll density gradient 
centrifugation 
Pig neutrophils were isolated as a standard for the bioassay of inflammation in 
pigskin. 20ml of pig blood was added to 2.2ml of 3.8% (v/v) citrate in a 50ml 
falcon tube. This solution was then centrifuged at 300g for 20 min at 20°C to 
separate the plasma and platelets from the red and white blood cells. After 
centrifugation, the platelet rich plasma (PRP) was removed, leaving the red 
and white blood cells. To the falcon tube containing the PRP, 2 - 3 ml of 90% 
(v/v) Percoll was added beneath the PRP layer and this was centrifuged at 
2000g for 20min (in order to remove the platelets from the plasma). Once the 
PRP had been centrifuged, the platelet poor plasma (PPP) was removed and 
kept for isolation of neutrophils on a Percoll gradient. 
To the tube containing the red and white blood cells, 2.5ml of 6% (w/v) 
dextran was added and the volume made up to 20 ml with normal saline. This 
tube was mixed by gentle inversion and allowed to settle at room temperature 
for 30 min (a process known as dextran sedimentation). 
The following solutions were prepared in order to create a percoll gradient: 
42% percoll = 10501-11 percoll + 14501-11 PPP 
51 % percoll = 12751-11 percoll + 12251-11 PPP 
After settling for 30min, the upper layer of leukocytes was removed from the 
tube that had undergone dextran sedimentation. This was then centrifuged at 
300g for 8min. After this time, the supernatant was removed and re-
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suspended with 2ml PPP. The percoll density gradient was then constructed 
in a falcon tube with 2mls of 51 % percoll on the bottom and 2ml of 42% 
percoll on the top. The leukocyte suspension was then added to this gradient 
and centrifuged at 260g for 11 min 30sec. After centrifugation, the plasma 
and monocyte layer were removed and the neutrophil layer extracted. The 
remaining PPP was added to the neutrophils and the solution centrifuged at 
170g for 8 min. The neutrophil pellet obtained was resuspended in 25ml of 
0.2% NaCI and 25ml of 1.6% NaCI (v/v) was then added. This resulted in 
lysis of any remaining red blood cells. A haemocytometer was used to 
perform a cell count and a cytospin at 100rpm for 5min was performed in 
preparation for a differential cell count. The slides were fixed and stained 
using Diff-quick (Dade Diagnostics, Aguada, PR) and a differential count 
performed manually under a light microscope using X400 objection. The 
remaining solution was centrifuged at 170g for 8 min and the neutrophil pellet 
obtained, re-suspended in 1 ml PGB Ca/MG solution (PBS, 20mM glucose 
and 0.5%BSA and 100mM Ca/Mg) and stored in the fridge until required but 
no longer than 4 hours. 
4.2.4 Preparation of porcine skin samples for myeloperoxidase assay 
Tissue levels of MPO can be used as a surrogate marker for neutrophils. 
Levels of MPO are reliably determined by assay, but tissue must first be 
homogenised in order to release any MPO present. 
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Tissue was homogenised using a small homogeniser (Footprint tools, 
Sheffield, UK) in 0.5% HTAB (hexa-decyl-trimethyl-ammonium bromide) using 
10mM MOPS (3-(N-Morpholino) propanesulfonic acid) at pH7 as the 
diluent. Pigskin disks were removed from liquid nitrogen and thawed on ice. 
All excess fat was removed with a scalpel and the disk weighed and cut into 
small pieces. The pieces were placed into 5 ml tubes and 2 ml of 
homogenisation buffer added. The tissue and buffer was kept on ice and 
homogenised for 10 bursts of 10 sec using a small rotor (Footprint Tools, 
Sheffield, UK). The homogenate was transferred to 2 ml eppendorf microfuge 
tubes and centrifuged at 4000 9 for 20 min at 4 ac. The supernatant was then 
stored at -20°C for later use. 
4.2.5 Preparation of standards for myeloperoxidase assay 
Porcine neutrophils, once extracted (see section 4.2.3), were used as a 
standard for each assay plate, using a maximum concentration of 0.35 - 0.45 
x 106/ml. 
4.2.6 Assay to detect the levels of myeloperoxidase in the skin samples 
The system used for this assay was an enzymatic reaction based on the 
peroxidase-catalyzed oxidation of 3,3', 5,5'tetramethylbenzidine (TMB) that 
resulting in the formation of a blue colour which could then be read optically 
on a plate reader at 620nm. 
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The assay was performed in a 96-well plate and each plate read at 620nm at 
room temperature, using Labsystems Genesis V3.05 software. To each of 
the required wells on a 96-well plate, 20 JlI of sample or standard and 180 JlI 
of diluted substrate solution were added in order. Colour development was 
allowed to proceed for 5 minutes and the plate was then read. The unknowns 
were compared with a known concentration of neutrophils using a standard 
curve generated by the Labsystems software. The optical density of samples 
without colour substrate was subtracted from equivalent samples with colour 
substrate. 
4.2.7 Immunostaining of wax embedded skin sections 
The skin sections were fixed in formalin for 24 hours and then transferred into 
phosphate buffered saline (PBS). They were then processed, embedded into 
paraffin wax and cut (approximately 5IJm thick) on a microtome by the 
Department of Histopathology, Northern General Hospital. They were then 
stained with haemotoxylin and eosin (H&E) by the Department of 
Histopathology, Northern General Hospital. The morphology of the tissue was 
examined after staining under light microscopy. Semi-quantification of 
absolute numbers of neutrophils by manual counting was made. 
4.2.8 Myeloperoxidasse staining of wax embedded sections of pig skin 
Myeloperoxidase staining was used to detect neutrophils. Sections were 
prepared as detailed in 4.2.7. In addition, in preparation for immunostaining, 
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slides to be stained were rehydrated (submerged in xylene for 10 min, then 
sequentially into 100% alcohol, 100% alcohol, 90% (v/v) alcohol and 70% 
(v/v) alcohol for 1 min). Slides were then incubated in 3% v/v hydrogen 
peroxide for 10 min in order to inhibit endogenous peroxidases and then 
washed in water. To block inappropriate activity of the secondary antibody, 
the slides were then incubated for 30 min at room temperature in a humidified 
chamber with 1 OOIJL per slide of 1 in 10 normal goat serum (NGS) + 1 % (w/v) 
Marvel (the serum used corresponded to the species in which the secondary 
antibody was raised). The NGS was removed and 100IJL of a primary 
myeloperoxidase monoclonal antibody (1 :350) (Vector Limited, UK) was put 
onto each slide and incubated for 1 h in the humidified chamber. Following 
incubation with the primary antibody, the slides were washed (3 x 5 min) and 
then further incubated in the humidified chamber at room temperature with 
1 OOIJL of biotinylated goat anti-rabbit antibody (1 :200, Vector Limited, UK) for 
30 min. The ABC reagents (Elite ABC-HRP kit, Vector) were mixed and 
incubated at room temperature for 30 min to form an avidin DH biotinylated 
horseradish peroxidase H complex. The avidin binds to the biotinylated 
secondary antibody whilst the peroxidase reacts with the chromagen DAB 
(diaminobenzidine tetrahydrochloride) to produce a brown precipitate. The 
slides were washed in PBS (3 x 5 min) and then placed back into the 
humidified chamber for 30 min and incubated with 1 OOIJL of tertiary antibody 
(ABC-HRP kit as described above). After incubation, the slides were washed 
(3 x 5 min) and then incubated with 100IJL DAB substrate for 5min. The 
slides were rinsed in running tap water for 1 min. Slides were counter stained 
with Carazzis Haemotoxylin for 1 min, rinsed in tap water and then 
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dehydrated through an ethanol series. The slides were then mounted in DPX 
mounting medium. Slides were viewed using light microscopy. 
4.2.9 Assessment of neutrophil recruitment to the skin 
Neutrophils are attracted to sites of inflammation by for example cytokine 
release. They therefore provide a good indicator of the extent and level of 
inflammation and were used as a surrogate marker of the inflammatory 
response in the experiments described in this chapter. 
4.2.10 Neutrophil extraction 
Neutrophils were extracted from pigs on the same day as the experiments for 
use as a standard in the MPO assay (sections 4.2.3 and 4.2.6). It was 
necessary to extract neutrophils each time the assay was performed as when 
frozen for use at a different time, the signal due to MPO activity deteriorated. 
The viability of the cells (as determined by trypan blue staining) also 
decreased after freezing (to <85% in all cases). In order to be certain that the 
concentration of neutrophils used for the standard was accurate, they were 
freshly prepared for each experiment. The viability (as determined by trypan 
blue staining) in all instances was >96% and each extraction consisted of 
>94% neutrophils as determined by Diff-quick (Dade diagnostics, Aguada, 
PR) staining. 
106 
4.3 RESULTS 
4.3.1 Neutrophil accumulation in response to intradermal injection of 
porcine IL.113 
Initial experiments were performed with no IL-1 ra in order to determine the 
baseline response to the intradermal injections. Figures 12 and 13 show that 
at all doses, intradermal injection of IL-1 ~ resulted in greater neutrophil 
accumulation than IL-1a. The maximal response for IL-1~ occurred in 
response to 1000Units IL-1 ~ and upward. Neutrophil recruitment was 
maximal when injections were performed at 4-6hours pre-death. These 
findings support the findings by Binns et al. who also found the maximum 
inflammatory response to be at 4h. For subsequent experiments, IL-1 ~ was 
used at a dose of 1000Units and injections were performed from 6 hours 
onwards (pre-death). 
4.3.2 Neutrophil accumulation in porcine skin after intradermal 
injection of porcine IL·113, with and with out implantation of 
subcutaneous mini pumps and iv bolus of IL·1 ra 
Figures 14 and 15 show the myeloperoxidase tissue levels after intradermal 
injection of IL-1~ at 1000Units or normal saline with and with-out iv bolus and 
sc infusion of IL-1 ra. As shown, after intradermal injection of IL-1 ~ 4 - 6 
hours pre-death, neutrophil accumulation is greatest. In view of this, tissue 
levels of MPO were determined from intradermal injections given from 6hours 
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Figure 12 Neutrophil accumulation in response to increasing doses of 
porcine IL-1 J3 
Note: The maximum inflammatory response occurred following injection of 
1000 Units of IL-1 p, 4 hours before sacrifice of the animal. Data are pooled 
from 3 different experiments, using 3 different animals and the injection sites 
are from different parts of the abdominal wall of the animal. Control tissue 
received saline only. 
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Figure 13 Neutrophil accumulation in response to increasing doses of 
intradermal injections of porcine IL-1a 
Note: The maximum response occurs after injection of 300 Units of IL-1 a 1 
hour before sacrifice of the animal. At all time-points, IL-1 a induces less of an 
inflammatory response that IL-1 p. Data are pooled from 3 different 
experiments, using 3 different animals and the injection sites are from 
different parts of the abdominal wall of the animal. Control tissue received 
saline only. 
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received no IL-1ra. Pink squares (-0-) (n=2) and triangles ( -~- ) (n=1) 
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demonstrate neutrophil accumulation in animals that received both an iv bolus 
and subcutaneous infusion of IL-1 ra at day 0 and day 3 respectively. 
Administration of IL-1 ra leads to near complete abolition of the inflammatory 
response induced by id IL-1 injection. (b) H&E staining, magnification X1000 
before reproduction, showing neutrophil infiltration after id injection of IL-1 beta 
1000Units, 6h before death. The arrows indicate the neutrophils. 
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Figure 15 MPO Immunostaining of skin sections taken from pigs 
without IL-1 ra and with IL-1 ra after id injection of IL-1 J3 6h before harvest 
The arrows demonstrate positive MPO staining. (a) Positively stained 
neutrophils can be seen. (b) there are no positively stained cells. 
Magnification x200 before reproduction 
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to death. Two pigs received an iv bolus of IL-1 ra and had mini-osmotic 
pumps inserted immediately prior to the first intradermal injection of IL-1 ~ 
(blue line on Figure 13). One pig received a bolus and had pumps inserted 3 
days prior to the intradermal wounding (pink line on Figure 14). In both 
instances, the recruitment of neutrophils to the skin is dramatically reduced to 
<10 x 106 per gram of skin. At the time of death, pieces of spleen were 
harvested and these were used as positive controls for each assay. Each 
piece of spleen had 250 - 300 x1 07 neutrophils per gram of tissue. After 
death, some skin that had not been injected was removed and assayed. 
These discs had <20x106 neutrophils per gram of tissue, as did skin that had 
been injected with normal saline after death. 
4.3.3 Histological analysis of wax embedded sections· Haemotoxylin 
and eosin staining 
Haemotoxylin and eosin (H&E) staining allowed neutrophils to be identified 
under light microscopy at x1 000 magnification (Figure 14b). Although the 
intention had been to quantify the number of neutrophils present, this was not 
possible for the following reasons: (1) each section was only 5~ thick and 
therefore a large number of sections would have to be analysed to get any 
meaningful results; (2) as the skin was only being used as a guide for dosing, 
it was felt to be more appropriate to determine the effects of IL-1 ra in the 
coronary artery; (3) neutrophils could only be accurately identified at x1 000 
magnification making counting very time-consuming; (4) depending on the 
angle the section was cut at it was felt likely that some neutrophils would be 
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sectioned obliquely and therefore missed on counting as they would not be 
easily identifiable. 
4.3.4 Histological analysis of wax embedded sections -
Myeloperoxidase Immunostaining 
Clear myeloperoxidase staining worked is shown in Figure 15, which 
illustrates disc sections taken from animals with and without IL-1 ra infusions. 
It can clearly be seen that in those animals that received IL-1 ra, the number of 
positive cells is dramatically reduced compared with sections from animals 
that did not receive IL-1 ra for the same time-point. This was not quantified 
because following assessment of multiple sections it became clear that this 
was an all or nothing response. 
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4.3 DISCUSSION 
4.3.1 Summary of findings 
Those data presented in this chapter provide evidence that after intradermal 
injection of IL-1J3 and IL-1a, there is neutrophil recruitment to pig skin, as 
demonstrated by the presence of myeloperoxidase (MPO). Numerous studies 
have used myeloperoxidase (a major constituent of neutrophil cytoplasmic 
granules) as a surrogate for neutrophil recruitment [102,105]. Mullane et al 
used myeloperoxidase activity as a quantitative assessment of neutrophil 
infiltration into ischaemic myocardium; other groups have used this assay on 
skin samples [105]. In these studies, IL-1 J3 appears to induce a greater 
inflammatory response than IL-1a. This is interesting as in most other cases 
their biological activity is i~distinguishable [14]. 
Neutrophil recruitment is maximal when IL-1 is injected 4 - 6 hr pre-death. 
This is in keeping with results from Binns et al who used radiolabelled 
neutrophils to study inflammation after intradermal injection of IL-1a into 
pigskin [100]. In these studies, the inflammatory response was maximal at 
4h, tailing off at 24 h (there was no intermediate time point), which is 
consistent with those data presented in this thesis. 
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4.3.2 Myeloperoxidase as a surrogate marker for neutrophils 
The experiments performed have provided a quantified measure of neutrophil 
recruitment (MPO assay) and these data have been supported with 
histological studies. The bioassay employed MPO as a surrogate marker and 
although this is well-established practice, actual neutrophil numbers were not 
quantified. Neutrophil recruitment to the inflammatory stimulus (in this case id 
IL-1 injection) could have been determined using radiolabelling techniques, 
but there would be uncertainty as to whether the radiolabelled cells were in 
the inflammatory lesion itself or the surrounding tissues. By employing a 
bioassay that allows the whole inflammatory lesion to be explanted and 
examined, this uncertainty is eliminated. Colorimetric assays are reproducible 
and comparisons between studies done on different days were easy with use 
of the standard curve. The dramatic response seen with IL-1 ra use indicates 
with certainty that there is complete inhibition of IL-1. 
4.4 Conclusions and future directions 
These data convincingly show that in animals that receive IL-1 ra, neutrophil 
recruitment to sites of IL-1 ~ intradermal injection is inhibited. Inhibition is 
maintained at 3 days when the effect of the intravenous bolus has worn off. 
Immunostaining of sections of pigskin for MPO provides added support for the 
data obtained by the assay. It is reported that IL-1 ra is required in 100 fold 
excess to IL-1~ to block its effects [14]. The response to IL-1ra in this study is 
dramatic with all neutrophil recruitment being effectively inhibited in pigskin. 
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The dose of IL-1 ra was 2mg/kg/24 hours, with a steady state of 150 -
250ng/ml and the dose of IL-1~ injected was 1000 Units (5ng), equivalent to a 
1000 fold excess of IL-1 ra. It may be that a dose of 2mg/kg/24 hr after an 
initial intravenous bolus of 0.5mg/kg is too high and the same effects could be 
seen with a lower dose of IL-1 ra. There are no data in the literature to provide 
any guidance as to what dose of IL-1 ra is enough. In terms of doses used in 
other trials, the dose we have used is consistent if not lower than doses 
currently undergoing clinical trial in humans [39, 40]. It is also important to 
note that the aim was to inhibit IL-1 activity in the coronary artery. IL-1 ~ is 
detected in porcine coronary arteries up to 14 days after injury [31]. The data 
presented here provide evidence that after delivery of IL-1 ra as described, 
circulating levels will be maintained at 150 - 250 ng/ml for 18 days ensuring 
adequate availability after injury. 
This initial work has demonstrated that IL-1 ra (at the dose studied) is a potent 
inhibitor of neutrophil recruitment to pigskin after local intradermal injection of 
IL-1~. It has further confirmed that human IL-1 ra can be used to inhibit 
porcine IL-1 and indicates testing this strategy in a porcine model of balloon 
injury and coronary stenting. 
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CHAPTERS 
MODULATION OF THE PORCINE CORONARY ARTERY RESPONSE TO 
OVERSIZED BALLOON ANGIOPLASTY AND STENTING 
5.1 INTRODUCTION 
5.1.1 Animal models of experimental injury and restenosis 
The ideal animal model for evaluation of restenosis is unclear. Generally, 
animal models serve to provide a mechanistic insight into biological processes 
rather than a means of predicting the human response to a treatment or 
intervention. Proof of concept studies can be performed and important 
information on issues such as toxicity of an agent can be examined. The 
coronary arteries of swine provide a good model for the study of restenosis 
(see section 5.1.2). The other animal model frequently used is the rabbit iliac 
artery [106, 107] but disadvantages of the rabbit model are that all studies are 
performed in peripheral arteries and therefore the effects on the heart such as 
arrhythmias are not identified. 
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5.1.2 Porcine coronary experimental injury model 
The pig has become the model of choice for studying the effects of vascular 
injury on the neointimal response in coronary arteries gaining wide 
acceptance over the past decade. The domestic pig (Sus scrofa) is a readily 
available species whose cardiovascular anatomy and physiology is similar to 
that of man [108]. In a 20 - 30kg pig, the heart - to - body size ratio is very 
similar to that of man [109]. The local proliferative response induced by 
interventional techniques (e.g. PTCA) is very similar in appearance in both pig 
and human coronary vessels [110]. In the pig, neointimal thickness resulting 
from vascular injury is directly proportional to the depth of the arterial injury, 
-
similar to the relationship thought to exist in humans [111]. Vascular damage 
induced by oversized intraluminal balloon injury in the porcine coronary artery 
can therefore be used as a model of arterial disease. 
5.1.3 Porcine coronary stent model 
This model provides a method for examining the impact of therapeutic agents 
on in-stent restenosis. It consists of normal swine coronary arteries injured by 
the placement of an oversized stent. Different ratios of over-sizing are used 
to provide differing levels of injury. A ratio of 1.1:1 will provide a mild injury, 
1.25:1 a moderate injury and 1.4:1 extensive injury. After 28 days, the 
animals are sacrificed and the hearts' perfusion fixed. The stented segments 
are removed, embedded and sectioned for histomorphometric analysis. The 
close histological resemblance between the lesions produced and human 
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restenosis, make it an excellent and widely used model [110]. Critics of the 
model point out that stents are placed into juvenile animals with normal 
hearts. 
5.1.4 Aims of this study 
The aim of this section of work was to determine the effect of IL-1 ra on the 
porcine coronary artery response to oversized balloon angioplasty and stent 
placement. 
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5.3 MATERIALS AND METHODS 
5.2.1 Experimentallnjury 
The effect of IL-1 ra on experimental injury i.e. coronary balloon angioplasty 
(PTCA) was assessed in the first instance. 12 pigs, providing 24 arteries 
underwent insertion of subcutaneous mini pump, iv bolus and then PTCA. A 
time-point of 28 days was studied. This was followed by experiments to 
determine the effects of IL-1 ra on restenosis following stent implantation. The 
BiodivYsio™ Phosphorylcholine (PC) coated intravascular stent was used in 
this study. All stents were either 3.0 mm or 3.5 mm in diameter and their 
lengths varied from 11 - 15 mm. The BiodivYsio™ stent is a flexible, balloon 
expandable, PC-coated stent composed of laser-cut 316L implant grade 
stainless steel metal tubing. The stent is mounted on a rapid exchange PTCA 
balloon delivery system, the PenChant™ delivery system. The PC coating 
has been shown previously to have no effect on neointimal formation in this 
model [112] 
5.2.2 Porcine coronary balloon angioplasty 
Each pig was sedated with an intramuscular injection of azaperone (12mg/kg, 
Janssen Animal Health). Anaesthesia was induced by intravenous propofol, 
(4mg/kg, Zeneca Pharmaceuticals) and maintained by inhaled enflurane (4-
6%) in oxygen (1 Umin) via endotracheal tube. Continuous 
electrocardiographic monitoring (Siemens) was performed through out the 
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experiment. In all animals, subcutaneous mini pumps were inserted into the 
groin immediately after anaesthesia at the start of the procedure. An incision 
was made along the groin crease between the ventral abdominal wall and the 
hind-leg, a pocket slightly larger than the size of 3 pumps created by blunt 
dissection, all 3 pumps inserted and then the skin was closed with a 
continuous running suture. The iv bolus of IL-1 ra was given after the heparin 
bolus, before manipulation of the catheter. 
A ventral midline neck incision was made to the right of the midline. The right 
carotid artery was exposed and an angiographic guide catheter manoeuvred 
under fluoroscopic guidance into the left or right coronary ostium (the surgical 
appearance is shown in Figure 16). Standard angiographic contrast medium 
(Hexabrix 320, Mallinkrodt) was used. A 6F right 1 Amplatz catheter was 
used to enter the left anterior descending artery (LAD) and a 7F right 2 
Amplatz catheter was used to enter the right coronary artery (RCA). All 
animals received 2500 U sodium heparin after insertion of the carotid sheath. 
No assessment of coagulation was performed. The balloon catheter was 
positioned over a guidewire in the coronary artery. Quantified digitised 
angiography (the lOIS system) was used to determine the site of balloon 
inflation such that the balloon/artery ratio was 1.25:1 (a 3.5 mm balloon in a 
2.8 mm section of the artery). The balloon was inflated 3 times at 8 
atmospheres for 10 seconds. An angiogram was performed at the end of 
each procedure to document arterial patency. After PTCA, the catheters were 
removed and the carotid artery ligated with a 2.0 Vicryl suture. The animal 
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Figure 16 Porcine percutaneous coronary intervention - the 
technique 
The carotid artery is exposed and a sheath inserted (a - e). Coronary artery 
guide catheters are inserted through the carotid sheath and manipulated into 
the ostia of the coronary arteries to perform angiography and PCI (f). At the 
end of the procedure, the carotid is ligated and the wound closed, allowing full 
recovery of the animal (g - i). 
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was allowed to recover. No neurological deficit occurred because of collateral 
supply from the contralateral carotid artery and the Circle of Willis. 
5.2.3 Porcine intracoronary stent placement 
Each pig was sedated and anaesthetised as in section 5.2.2. Continuous 
electrocardiographic monitoring (Siemens) was performed through out the 
experiment. 
Animals received an iv bolus and had sc pumps implanted as in section 5.2.2. 
In all animals that received a 2Bd infusion, at 14d, another incision was made 
in the contralateral groin crease and a pocket created as before. 3 new 
pumps were inserted and the pocket closed. The original pocket was left 
alone with the pumps in situ. 
Angiography was performed as in section 5.2.2 but instead of oversized 
balloon angioplasty, intracoronary stents were inserted. Pre-mounted 
BiodivYsio Penchant PC coated stents (Abbott Vascular Ltd) were deployed 
into both the LAD and the RCA. Quantified digitised angiography (the lOIS 
system) was used to determine the site of stent deployment such that the 
stent/artery ratio was 1.25:1 (a 3.5 mm stent in a 2.B mm section of the artery 
and a 3.0 mm stent in a 2.4 mm section of artery). Balloon inflation was at 
Batmospheres for 30 seconds. After stent deployment, the catheters were 
removed and the carotid artery ligated. Each animal received 150mg of oral 
aspirin for 5 days, starting the day before the procedure. An angiogram was 
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performed at the end of each procedure to document arterial patency. The 
animal was allowed to recover. No neurological deficit occurred because of 
collateral supply from the contralateral carotid artery and the Circle of Willis. 
5.2.4 Artery extraction and tissue processing 
At selected time intervals post-procedure, pigs were re-sedated with 
azaperone (12mg/kg, Janssen Animal Health) and a lethal intravenous 
overdose of pentobarbitone sodium (Animalcore Ltd, Dinnington, York, UK ) 
administered. A median sternotomy was performed and the whole heart 
explanted and washed in 0.09% saline. For the angioplastied vessels, the 
-
whole heart was perfusion fixed in 10% (v/v) formalin at 100mmHg for 15 - 30 
minutes. Pressure was maintained using a pressure bag. Following fixation, 
the angioplastied vessel was removed in its entirety, serially cross-sectioned 
from proximal to distal into blocks of tissue 2-3 mm long and immersion fixed 
in formalin for 24h before transferral into PBS. Once in PBS, segments were 
kept at 4°C pending embedding in paraffin wax for histology. For the stented 
vessels, no formalin fixation was performed; the 3.5 mm stents were identified 
and excised in situ. Each vessel was flushed through with 0.09% saline, and 
immersion fixed in formalin for 24h and then transferred into PBS and kept at 
4°C pending embedding in methyl-methacrylate resin. 
125 
5.2.5 Histology 
The angioplastied artery blocks for light microscopy were embedded in 
paraffin wax and a microtome used to cut 4j..lm thick cross-sections. These 
were stained with haematoxylin and eosin or Miller's elastin and van Gieson's 
stain (to reveal elastin and fibrous tissue) and viewed under conventional light 
microscopy. The sections of normal artery that had not undergone balloon 
angioplasty were identified and excluded from analysis. Angioplastied artery 
was identified by breaches in the elastic laminae of the vessel wall, indicating 
injury. The stented vessels were all embedded in methyl-methacrylate resin. 
Briefly, the whole explanted section of artery was dehydrated in acetone for 
24h and then embedded into a methyl methacrylate resin (Technovik 8100, 
Taab laboratories, Berkshire, UK). Each artery was serially sectioned using a 
Buehler Isomet diamond edged saw. The section obtained was further 
ground and polished using a Metaserv 2000 grinder/polisher (Buehler) 
resulting in a section of artery, 20 - 30j..lm thick. This method leaves the stent 
in situ and the tissue undamaged, enabling accurate assessment of tissue 
morphology [113]. 
5.2.6 Histomorphometric analysis 
Sections of artery were examined using a quantitative method of histo-
morphometric analysis. The system comprised a Nikon Eclipse E600 
microscope and a Basler camera attachment with output to a computerised 
image analysis system (Lucia Image Analysis Software, Nikon, UK). After 
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suitable calibration, a hand-held mouse was used to trace round the arterial 
wall layers (see Figure 17 for the angioplastied sections and Figure 23 for the 
stented sections). The Lucia software calculated distances and areas. The 
cross-sectional areas (CSAs) of the lumen, neointimal, media, adventitia, 
stent and whole vessel were recorded and an injury score for each section 
determined (see 5.2.7). All injured sections that had undergone PTCA were 
analysed. For the PTCA group, sections that were incomplete, had branch 
distortion or tissue loss were rejected. For the stented vessels, using the 
technique described above, multiple sections were obtained from each artery. 
Alternate sections were analysed and sections were rejected on the grounds 
of an incomplete ring of struts or branch distortion. On average 4 - 6 sections 
were analysed per PTCA vessel and 6 - 10 per stented vessel. 
5.2.7 Arterial injury score and corrections 
The lengths of breaches in the external elastic lamina (EEL) and the internal 
elastic lamina (IEL) were recorded for the angioplastied sections. The lengths 
of breaches were converted to % total EEL or IEL circumference. This was 
used as a basic injury score for the angioplastied vessels. The ratio of 
intima/media area was calculated, allowing for larger vessels having greater 
dimensions. This ratio was further divided by the % IEL breach in an attempt 
to correct the amount of neointimal formation for the degree of trauma. 
For the stented sections, each strut was assigned an injury score according to 
previously defined criteria. Two previously established scores were used, the 
Schwartz injury score [114] and the Modified Schwartz injury score [115]. 
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Figure 17 
Vessel Area ------;:-:0:.::1 
EEL 
Adventitia 
IEL 
Neointima 
Measurements taken for histomorphometric analysis of 
PTCA sections 
Each arterial layer is traced using a hand-held mouse and the cross-sectional 
area determined by the Lucia software 
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Briefly, the Schwartz score assesses whether the IEL, EEL and media have 
been ruptured or not. It assigns each strut a score from 0 - 3 according to the 
following criteria. 0, no rupture; 1, ruptured IEL; 2, ruptured media; and 3, 
complete EEL rupture. The modified Schwartz (Gunn) injury score utilises a 
score from 0 - 4 and differs from the Schwartz score in that it takes into 
account strut impaction and stretch. 0, no impression of metal upon media; 1, 
deformation of the IEL <45°; 2, deformation of the IEL > 45°; 3, rupture of the 
IEL; 4, rupture of the EEL (that is, complete medial rupture). The score for 
each section was the mean of the individual strut scores. To account for 
vessel size, each parameter was divided by the total vessel area and then a 
further correction for injury was made by dividing the size corrected parameter 
by the mean injury score for each section. ' 
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5.4 RESULTS - PTCA section analysis 
5.3.1 Histomorphometric analysis of PTCA sections 
For all of the following results, there were 6 pigs in each treatment group 
yielding 12 vessels per group. Histological examination of all of these 
sections revealed a varying amount of injury (as determined by the degree of 
IEL breach) that ranged from no injury to extensive disruption. Of the vessels 
studied, 50 sections had injury and were suitable for analysis in the IL-1 ra 
treated group and 51 sections in the vehicle treated group. All data are 
presented as mean ± SEM and significance determined using an unpaired 
Students't-test. 
5.3.2 PTCA section analysis 
The measurements taken for each PTCA section are shown in figure 17. All 
analyses were operator blinded and two independent observers measured all 
sections. There was no significant difference between the values obtained (p 
> 0.85 for all measurements with < 10% magnitude of difference between the 
two observers). 
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5.3.3 Total vessel cross-sectional area for PTCA sections 
The cross-sectional area of the total vessel was calculated. As figure 18a 
shows, there is no significant difference between the vehicle and IL-1 ra 
treated groups with respect to vessel size. 
5.3.4 Injury score 
The injury score for the PTCA sections was determined by the % breach of 
the internal elastic lamina (IEL). The lengths of breaches were converted to 
% totallEL circumference. This value was used as an injury score for the 
angioplastied vessels. Figure 18b shows the difference in %IEL breach 
between the IL-1 ra and Vehicle treated groups. Although there is a trend for 
more injury in the vehicle treated animals, this does not reach significance. 
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Figure 18 Modulation of PTCA Injury by IL-1ra: (a) Total Vessel 
Cross-sectional area (mm2) and (b) % IEL breach (injury score) 
The data are expressed as mean (± SEM). (a): There is no significant 
difference between the two groups (n=6, p = 0.68). (b): There is no significant 
difference between the two treatment groups (n=6, p = 0.13), although there is 
a trend towards increased injury in the vehicle treated animals. 
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5.3.5 Neointimal area of the PTeA sections 
The intimal thickening that occurs in response to injury is shown in this model 
by an increase in neointimal area (mm2). Figure 19 demonstrates that when 
the animals receive an iv bolus of IL-1 ra followed by a continuous 
subcutaneous infusion, there is a 23% decrease in neointima formation and 
the response to injury which is significant (p <0.04). 
5.3.6 Lumen area of the PTeA sections 
The cross-sectional area of the lumen is shown in Figure 20. As expected, 
the animals that received IL-1 ra and had a smaller amount of neointima have 
a larger lumen although the difference seen does not reach significance. 
5.3.7 Intima: media ratio of the PTeA treated arteries 
In order to correct for differences in vessel size between the animals, the 
neointima area is divided by the cross-sectional area of the media for each 
section. Figure 21 a demonstrates that when vessel size is accounted for, 
there is a significant reduction in neointima area (p = 0.01). As previously 
discussed, each section has a differing amount of injury. In order to account 
for this, each intima: media ratio is further divided by the injury score for each 
section i.e. the % IEL breach. Figure 21 b shows that even with this further 
correction, the effect of IL-1 ra on reducing neointimal area is still significant (p 
= 0.04). Representative histological sections are shown in Figure 22. 
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Figure 19 Modulation of PTCA Injury by IL-1 ra: Neointimal cross-
sectional area (mm2) 
The data are presented as mean ± SEM). There is a significant difference 
between the two groups (n=6, * p = 0.04), with less neointima formation in the 
IL-1 ra treated animals. 
134 
2 
-N E 
E 
-~ 
Q) 
.... 
~ 
c: 
Q) 
E 
:::s 
...J 
0 
Vehicle IL-1ra 
Figure 20 Modulation of PTCA Injury by IL-1 ra: Cross-sectional area 
of the lumen (mm2) 
The data are presented as mean ± SEM. There is no significant difference 
between vehicle and IL-1 ra treated vessels (n=6, p = 0.08), although there is 
a trend towards an increased lumen in the IL-1 ra treated group. 
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Figure 21 Modulation of PTCA Injury by IL·1 ra corrected for vessel 
size and injury 
The uncorrected (a) and corrected (b) intima: media ratio of PTCA treated 
arteries are shown above. In both cases, IL-1 ra results in significantly less 
neointima formation, even with a correction for vessel size and injury (n=6, * p 
= 0.006; and p = 0.04). 
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Figure 22 Tissue response to PTCA in porcine coronary arteries 
Histological sections from pig coronary artery following PTCA are shown. IL-
1ra infusion was for 14-days and analysis was at 28-days. (a) shows a 
section of coronary artery from an animal that received IL-1 ra and (b) shows a 
corresponding section from a vehicle treated animal. 80th sections have 
been stained with Miller's elastin and van Gieson's stain. 80th show a 23% 
breach in the internal elastic lamina. There is clearly much less neointima in 
the IL-1 ra treated vessel. 
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5.4 RESULTS - Intracoronary stenting 
5.4.1 Histomorphometric analysis of stented sections 
For all of the following results, there were 6 pigs in each treatment group, 
apart from the final 90 day time-point in which there were 4 animals. This 
yielded 8 -12 vessels per group. Histological examination of all of these 
sections revealed a varying amount of injury (as determined by the previously 
described injury score) that ranged from no injury to extensive disruption. The 
initial group of animals studied received a 14-day infusion and sacrifice was at 
28-days. A 28-day time-point is traditionally studied with the porcine model as 
this has been shown previously to be approximately comparable with 6 
months in the human (the time-point within which restenosis traditionally 
occurs) [116]. Shorter time-points give extra information as to the processes 
occurring following stenting. Sectioning each artery as described in 5.2.4 
yields 15 - 20 sections per vessel. This gives 6 - 10 sections per vessel that 
are analysable. Figure 23 demonstrates the measurements taken for each 
section. Analysis was operator blinded and two independent observers 
me~sured all sections. There was no significant difference between the 
values obtained (p > 0.85 for all measurements with < 10% magnitude of 
difference between the two observers). All data are presented as mean ± 
SEM and Significance determined using an unpaired Students' t-test. 
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Figure 23 Measurements taken for histomorphometric analysis of 
stented sections 
Histomorphometric measurements made 
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5.4.2 Analysis: 14-day infusion, 28-day time-point 
The following data are for animals which have received a 14-day infusion of 
either IL-1 ra or vehicle and that have been killed at 28-days. 112 sections 
were suitable for analysis in the IL-1 ra treated group and 98 sections in the 
vehicle treated group. 
5.4.2.1 Total vessel cross-sectional area 
Figure 24 shows that there is no significant difference between the two 
treatment groups with respect to vessel size. 
5.4.2.2 Injury Score 
The injury score shown is the Modified Schwartz (Gunn) injury score. Figure 
25 shows that there is a trend for more injury in the vehicle group but this 
does not reach statistical significance (p=0.06). Although not shown, when 
the Schwartz injury score is calculated, there is also no significant difference 
between the two groups (p = 0.50). 
5.4.2.3 Neointima area 
The data shown in Figure 26a is the raw neointima area. After a 14-day 
infusion of drug and a 28-day sacrifice, there is a significant increase in the 
neointima area in the IL-1 ra treated animals (p < 0.001). The data shown in 
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Figure 24 Modulation of intracoronary stenting by IL-1 ra (14d 
infusion, 28d analysis): Cross sectional vessel area 
Animals received a 14-day infusion of either IL-1 ra or vehicle. Animals were 
killed at 2B-days. There is no significant difference between the two groups 
(n=6, p = O.OB) 
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Figure 25 Modulation of intracoronary stenting by IL-1ra (14d 
infusion, 28d analysis): Injury score correction 
No significant difference between groups is seen (n=6, p = 0.06). 
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Figure 26b is the corrected neointima area, that is the neointima area 
corrected for both vessel size and injury. After a 14-day infusion of drug and 
a 28-day sacrifice, there is a significant increase in the corrected neointima 
area in the IL-1 ra treated animals (p < 0.001). Representative histological 
sections are shown in Figure 27. 
5.4.2.4 Cross-sectional lumen area 
The lumen area was calculated for each section. When comparing the two 
treatment groups, it can be seen from Figure 28 that there is a significant 
difference between the two groups (p = 0.02). 
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Figure 26 Modulation of intracoronary stenting by IL-1 ra (14d 
infusion, 28d analysis): Neointima Area 
Uncorrected (a) and corrected (b) neointima area of porcine coronary arteries 
following stenting and IL-1 ra or vehicle infusion. In both cases, in contrast to 
PICA treated arteries, IL-1 ra causes a significant increase in neointima area 
(n=6, p< 0.001). 
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Figure 27 Tissue response to Intracoronary stenting (14 day infusion, 
28 day analysis). 
80th these histological sections are representative of the sections obtained 
from (a) IL-1 ra treated animals and (b) placebo treated animals. For a similar 
degree of injury, there is more neointima in the IL-1 ra treated group 
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Figure 28 Modulation of intracoronary stenting by IL-1 ra (14d 
infusion, 28d analysis): Lumen Area 
There is a bigger lumen in the vehicle treated group (n=6, p = 0.02). 
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5.4.3 Analysis: 14-day infusion, 14-day time-point 
The following data are for animals which have received a 14-day infusion of 
either IL-1 ra or vehicle and that have been killed at 14-days. 83 sections 
were suitable for analysis in the IL-1 ra treated group and 82 sections in the 
vehicle treated group. 
5.4.3.1 Total vessel cross-sectional area 
The cross-sectional area for each section was calculated. Data are presented 
as mean and standard error of the mean for each treatment group. Figure 29 
shows that there is no significant difference between the two treatment 
groups. 
5.4.3.2 Injury Score 
The injury score shown is the Modified Schwartz (Gunn) injury score that 
takes into account stretch as well as fracture of the elastic laminae. Figure 30 
shows that there is no significant difference between the two treatment groups 
(p=0.44). Although not shown, when the Schwartz injury score was 
calculated, there is also no difference between the two groups. 
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Figure 29 Modulation of intracoronary stenting by IL-1 ra (14d 
infusion, 14d analysis): Total vessel cross-sectional area 
There was no significant difference between the two treatment groups (n=6, 
p=O.11 ). 
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Figure 30 Modulation of intracoronary stenting by IL-1 ra (14d 
infusion, 14d analysis): Injury score correction 
After application of the Modified Schwartz (Gunn) injury score, there was no 
significant difference between the two treatment groups (n=6, p = 0.44). 
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5.4.3.3 Neointimal area 
Figure 31 a shows the uncorrected neointima area after IL-1 ra or vehicle 
treatment of stented porcine coronary arteries. There was a significant 
decrease in neointima area with IL-1 ra treatment (p < 0.001). In order to take 
into account vessel size and the degree of injury for each section, the cross-
sectional neointimal area for is section has been corrected by dividing the 
value obtained by the vessel size followed by a further correction for the mean 
injury score of that section. Figure 31 b shows that when comparing the two 
treatment groups, IL-1 ra significantly reduces the neointimal response to 
injury (n=6, p < 0.0001). Figure 32 shows representative histological sections 
from each treatment group. 
5.4.3.4 Cross-sectional lumen area 
The lumen area was calculated for each section. Given the reduced 
neointima in the IL-1 ra treated group (see section 5.4.3.3), it follows that 
treatment with IL-1 ra also results in a Significantly larger lumen than treatment 
with vehicle (n=6, p < 0.0001, Figure 33). 
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Figure 31 Modulation of intracoronary stenting by IL·1 ra (14d 
infusion, 14d harvest): Neointima Area 
Uncorrected (a) and corrected (b) neointima area of porcine coronary arteries 
following stenting and IL-1 ra or vehicle infusion for the duration of the 
experiment (14-days). In both cases, as with PTCA treated arteries, IL-1 ra 
causes a significant decrease in neointima area (n=6, p< 0.001). 
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Figure 32 Tissue response to Intracoronary stenting (14 day infusion, 
14 day analysis). 
Both these histological sections are representative of the sections obtained 
from (a) IL-1 ra treated animals and (b) placebo treated animals. For a similar 
degree of injury, there is less neointima in the IL-1 ra treated group 
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Figure 33 Modulation of intracoronary stenting by IL-1 ra (14d 
infusion, 14d analysis): Lumen Area 
Vessels were harvested at 14-days. There is a bigger lumen in the IL-1 ra 
treated group (n=6, p < 0.0001). 
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5.4.4 Analysis: 28-day infusion, 28-day time-point 
The following data are from animals which have received a 28-day infusion of 
either IL-1 ra or vehicle and that have been killed at 28-days. 69 sections 
were suitable for analysis in the IL-1 ra treated group and 64 sections in the 
vehicle treated group. 
5.4.4.1 Total vessel cross-sectional area 
The cross-sectional area for each section was calculated. Data are presented 
as mean and standard error of the mean for each treatment group. Figure 34 
shows that there is no significant difference between the two treatment 
groups. 
5.4.4.2 Injury Score 
The injury score shown is the Modified Schwartz (Gunn) injury score. Figure 
35 shows that there is a significant difference between the two treatment 
groups with more injury in the IL-1 ra treated group (n=6, p=O.001). Although 
not shown, when the Schwartz injury score is calculated, there is no 
significant difference between the two groups. This highlights the difference 
between the two scores (see section 5.4.4.3). 
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Figure 34 Modulation of porcine coronary artery response to stenting 
by IL-1 ra (28d infusion, 28d analysis): Total vessel cross-sectional area 
(mm2) 
There was no significant difference between the two treatment groups (n=6, 
p=O.90). 
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Figure 35 Modulation of porcine coronary artery response to stenting 
by IL-1 ra (28d infusion, 28d analysis): Injury Score correction 
There is a significant difference between the two treatment groups with far 
more injury in the IL-1 ra treated animals (n=6, p = 0.001). 
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5.4.4.3 Neointima area 
Figure 36 shows the uncorrected and corrected neointima area data following 
stenting in the 28 day infusion and 28 day analysis group. The importance of 
the correction for injury score is specifically highlighted by these data since in 
the uncorrected group of animals (Le. when vessel size and injury score are 
not accounted for), there is no significant decrease in neointima area with IL-
1 ra treatment (Figure 36a) (n=6, p = 0.33). In order take into account vessel 
size and injury, the neointima area is corrected by dividing the value obtained 
by the vessel size followed by a further correction for the mean injury score of 
that section (Figure 36b). When the correction is applied, it reveals that when 
comparing the two treatment groups, IL-1 ra significantly reduces the 
neointimal response to injury (n=6, p < 0.0005). This highlights the 
importance of the correction for injury, especially when the injury scores differ 
in the two groups as in this case. Again representative histological sections 
c) 
from each treatment group are shown (Figure 37). 
5.4.4.4 Cross-sectional lumen area 
The lumen area was calculated for each section. When treatment is 
continued for 28-days, there is no significant difference in lumen size with IL-
1 ra although there is a trend for a bigger lumen in the IL-1 ra treated group 
(n=6, p = 0.30, Figure 38). 
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Figure 36 Modulation of porcine coronary artery response to stenting 
by IL·1 ra (28d infusion, 28d analysis): Neointima Area 
Uncorrected (a) and corrected (b) neointima area of porcine coronary arteries 
following stenting. With no correction (a), there is no significant difference 
between the two treatment groups (n=6, p = 0.33). When a correction for 
vessel size and injury is made, as with PTCA treated arteries (b), IL-1 ra 
causes a significant decrease in neointima area (* n=6, p< 0.0005). 
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Figure 37 Tissue response to Intracoronary stenting (28 day infusion, 
28 day analysis). 
Both these histological sections are representative of the sections obtained 
from (a) IL-1ra treated animals and (b) placebo treated animals. As with the 
14 day infusion and 14 day analysis animals, for a similar degree of injury, 
there is less neointima in the IL-1 ra treated group 
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Figure 38 Modulation of porcine coronary artery response to stenting 
by IL-1 ra (28d infusion, 28d harvest): Lumen area (mm2) 
There is a bigger lumen in the IL-1 ra treated group although this does not 
reach significance (n=6, p = 0.30). 
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5.4.5 Analysis: 28-day infusion, gO-day time-point 
The following data are from animals which have received a 28-day infusion of 
either IL-1 ra or vehicle and that have been killed at 90-days. There were 4 
animals in each group. 50 sections were suitable for analysis in the IL-1 ra 
treated group and 44 sections in the vehicle treated group. 
5.4.5.1 Total vessel cross-sectional area 
The cross-sectional area for each section was calculated. Data are presented 
as mean and standard error of the mean for each treatment group. Figure 39 
shows that there is no significant difference in vessel area between the two 
treatment groups. 
5.4.5.2 Injury Score 
The injury score shown is the Modified Schwartz (Gunn) injury score. Figure 
40 shows that there is no significant difference between the two treatment 
groups. 
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Figure 39 Modulation of porcine coronary artery response to stenting 
by IL·1 ra (28d infusion, 90d analysis): Vessel area (mm2) 
There was no significant difference between the two treatment groups (n=4. 
p=O.06). 
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Figure 40 Modulation of porcine coronary artery response to stenting 
by IL-1 ra (28d infusion, 90d analysis): Injury Score 
There is no significant difference between the two treatment groups (n=4, p = 
0.69). 
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5.4.5.3 Neointima area 
Figure 41 shows the uncorrected and corrected neointima area data following 
stenting in the 28 day infusion and 90 day analysis group. The raw neointima 
area (Figure 41 a) shows a significant difference between the two treatment 
groups with less neointima following IL-1 ra therapy (n=4, p < 0.0001). When 
the data is corrected as described in 5.4.4.3, the significant difference 
between the two groups in favour of IL-1 ra is maintained (Figure 41 b) (n=4, p 
< 0.000001). Figure 42 shows histological sections from each group, 
highlighting the difference in neointima seen. 
5.4.5.4 Cross-sectional lumen area 
The lumen area was calculated for each section. When treatment is 
continued for 28-days, and the harvest performed at 90 days, there is a larger 
; 
lumen size with IL-1 ra treatment (n= 4, p < 0.005, Figure 43). 
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Figure 41 Modulation of porcine coronary artery response to stenting 
by IL-1 ra (28d infusion, 90d analysis): Neointima Area 
Uncorrected (a) and corrected (b) neointima area of porcine coronary arteries 
following stenting. With no correction (a), there is a significant difference 
between the two treatment groups (n=4, * p < 0.0001). When a correction for 
vessel size and injury is made (b), IL-1 ra still causes a significant decrease in 
neointima area (* n=4, p< 0.000001 ). 
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Figure 42 Tissue response to Intracoronary stenting (28 day infusion, 
90 day analysis). 
Both these histological sections are representative of the sections obtained 
from (a) IL-1 ra treated animals and (b) placebo treated animals. For a similar 
degree of injury, there is 41 % less neointima in the IL-1 ra treated group 
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Figure 43 Modulation of porcine coronary artery response to stenting 
by IL-1 ra (28d infusion, gOd analysis): Lumen area (mm2) 
There is a bigger lumen in the IL-1 ra treated group which reaches significance 
(n= 4, p < 0.005). 
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5.5 DISCUSSION 
5.5.1 Summary of findings 
The work in this chapter has shown that antagonism of IL-1 by IL-1 ra inhibits 
neointima formation after coronary artery injury and stenting in a porcine 
model. In the case of PTCA, IL-1 ra resulted in a 23% decrease in neointima 
area, independent of the length of IL-1 ra therapy. In the case of stenting, IL-
1 ra inhibited neointima formation for the duration of the infusion, but after 
cessation of the infusion around 14 days, there was a 'catch-up' phenomenon, 
with a 34% larger neointima in IL-1 ra treated arteries than vehicle. However, 
if the infusion is continued for 28 days and the vessels harvested at 90 days, 
again there is a 41 % decrease in neointima area. It seems likely therefore 
that that there is a critical length of infusion needed to suppress neointima 
formation and that the chronic inflammatory response caused by the stent 
I 
struts needs prolonged (28 days) suppression for after implantation. 
5.5.2 The effect of IL·1 ra on the vessel response to balloon angioplasty 
IL-1 ra treatment results in significantly less neointima formation than in 
vehicle treated arteries. Although over 90% of procedures now involve 
placement of a stent, there are still instances when balloon angioplasty in 
isolation is used, e.g. in tortuous arteries when a stent cannot physically be 
placed into the vessel or in very small vessels where the use of stents 
remains controversial because the published data reveals disparate results 
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[117]. Injury following balloon angioplasty is different to injury following 
stenting. Balloon injury is analogous to acute fissuring of the vessel, with 
thrombus accumulation and healing taking place immediately following 
disruption. Stenting is a chronic stimulus that produces profound neointima 
formation. The inflammatory process following balloon angioplasty is 
therefore shorter than that post-stenting. The 14-day infusion of IL-1 ra is long 
enough to cover the acute inflammatory process following PTCA and after 
that healing occurs so a prolonged infusion of IL-1 ra is not necessary. The 
23% reduction in neointima seen in this study is impressive following balloon 
only angioplasty. Early drug delivery strategies using a "leaky" balloon were 
cumbersome, dangerous, wasteful and ultimately unsuccessful. It follows that 
a systemic approach to therapy may be more appropriate following balloon 
angioplasty than a local drug delivery one. This aside, the fact remains that 
the majority of lesions are treated with intracoronary stent placement and 
balloon only angioplasty has a limited remit. 
5.5.3 The effect of IL·1 ra on the vessel response to intracoronary 
stenting. 
Following intracoronary stent placement, there is a significant reduction in 
neointima formation following IL-1 ra therapy for the duration of the experiment 
(38% following 14-days and 34% after 28-days of treatment). If the infusion is 
continued for 28 days and the vessels harvested at 90 days, the inhibition of 
neointima is maintained at 41 %. However, if the infusion is stopped early, 
there is rebound neointima formation (with 34% more neointima in the IL-1 ra 
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treated animals). When sirolimus and paclitaxel were given for 28 days in a 
porcine model of stenting, they caused a 50% and 39.5% respective reduction 
in neointima formation [118, 119], which is comparable to the results seen in 
this study. However when a 90 day time-point is considered, the results differ 
greatly. When pigs undergo intracoronary stenting with a Sirolimus eluting 
stent and the vessels are harvested at 90 days, there is no longer 
suppression of neointima formation and the amount of neointima seen in the 
Sirolimus-eluting stents equals that of the control bare metal stent [118]. 
Similarly, when Paclitaxel eluting stents are placed into rabbit arteries and the 
vessels harvested at 90 days, despite an initial impressive reduction in 
neointima formation at 30 days, at 90-days the effect is lost with no significant 
difference between the Paclitaxel eluting stents and the bare metal stents 
[119]. It seems likely therefore that for prolonged inhibition of neointima 
formation in the porcine model, an anti-inflammatory approach may give 
better suppression of neointima than an anti-proliferative one ..•.. 
I 
The increase in neointima formation seen when IL-1 ra is discontinued 
between 14 and 18-days and analysis cond ucted at' 28-days was a surprising 
finding. The reduction of neointima at 28-days when the IL-1 ra was continued 
for the complete duration of the study indicates not only the importance of IL-1 
in this process, but also indicates the duration of the IL-1 mediated response 
following stenting. Since neointima is also reduced at 90 days after IL-1 ra 
treatment for 28 days, this indicates that the duration of the 'IL-1 ra inhabitable' 
inflammatory response following stenting is between 14 and 28-days. This 
stenting response also contrasts with the PTCA response (balloon angioplasty 
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alone with 14-day IL-1ra and analysis at 28-days), when a reduction in 
neointima was induced. Since PTCA is a 'one-off injury, it appears that a 14-
day infusion of IL-1 ra is sufficient to have inhibitory effects upon distant (28-
day) responses. The stenting response to this regime of IL-1 ra however 
suggests that the injury resulting from stent placement causes a more chronic 
inflammatory stimulus. This has to be presumed to arise from the vessel wall 
cells as inflammatory white cells and platelets are not a prominent feature at 
14-days and beyond. We hypothesized that the IL-1 ra infusion could not only 
be inhibiting IL-1 signalling but also inhibiting IL-1 production, and that 
discontinuation of the IL-1 ra around 14-days was associated with a rebound 
production of IL-1. 
5.5.4 Implications of findings 
This work is the first to show that IL-1 is directly involved in th~ vessel wall 
response to injury and in neointima formation after intracoronary stenting. 
This work is also the first to use a purely anti-inflammatory agent to inhibit 
neointima formation. The agents in current clinical 'use for suppression of 
neointima such as sirolimus and paclitaxel are in the main, cytostatic [76] 
[120]. An anti inflammatory strategy, using IL-1 ra is novel and, if these results 
translate to man may prove an effective alternative or additional treatment in 
coronary heart disease. It may be that certain patterns of coronary heart 
disease (e.g. acute coronary syndromes), which are associated with 
'inflammatory' lesions, may be particularly suitable for an anti-inflammatory 
approach in the context of therapeutic PCI. When considering prolonged 
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suppression of neointima, these data show that unlike the cytostatic agents, 
IL-1 ra causes prolonged suppression of neointima formation at 90 days post 
stent implantation. This is potentially important when considering the long-
term effects of these agents. 
5.6 Conclusions and future directions 
Following balloon angioplasty, IL-1 ra results in a significant reduction in 
neointima formation. The same is true following stenting but the reduction is 
only seen if the infusion of IL-1 ra is continued for the length of the experiment. 
If it is stopped early, a 'catch up' in neointima is seen, with more neointima 
being formed in the IL-1 ra treated animals. When a longer time point of 90 
days is studied, suppression of neointima is maintained despite the IL-1 ra 
only being given for the first 28 days. In order to determine the appropriate 
therapy length for IL-1 ra treatment, it is important to determine. the mechanism 
of the 'catch-up' phenomenon seen. We know from the literature that IL-1 P is 
present in the arterial wall up to 3 days following balloon angioplasty [31]. To 
1 
test the hypothesis that the 'catch up' occurred because of a rebound in IL-1 
production, Western blotting and Real-time quantitative peR were used to 
assess IL-1 production in the vessel wall. 
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CHAPTER 6 
MECHANISM OF ACTION OF IL-1 ra IN THE VESSEL WALL AFTER 
STENTING 
6.1 INTRODUCTION 
The only known action of IL-1 ra is to inhibit IL-1 by competitively binding to 
the Type 1 receptor. Therefore, the rebound increase in neointima formation 
seen following discontinuation of IL-1 ra therapy must involve IL-1 in some 
way. The hypothesis behind the work presented in this chapter was that 
discontinuation of IL-1 ra led to an increase in vessel wall production of IL-1. 
The work presented here attempted to determine whether, at both the protein 
and mRNA level, there was an increase in vessel wall IL-1. 
6.1.1 Regulation of production of IL-1 
The majority of microbial products induce IL-1 ~ via the Toll like receptor family 
of receptors. Depending on the stimulant, IL-1 ~ mRNA levels rise quickly but 
by 4 hours start to decline. This decline is thought to be due to the local 
production of a transcriptional repressor and/or a decrease in mRNA half-life 
[121]. IL-1~ can stimulate its own gene expression and when it does, mRNA 
levels are sustained for over 24 hours. IL-1 a also stimulates IL-1 ~ gene 
expression via a cyclic-AMP mediated process [122]. The primary sources of 
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IL-1 ~ protein are blood monocytes and macrophages. ATP results in the 
rapid release of mature IL-1 ~ and because of this observation, a receptor-
mediated release event via an ion channel has been proposed although not 
yet fully proven. 
6.1.2 Quantification of tissue levels of IL-1 
When considering IL-1 biology and its regulation, it is often necessary to 
quantify the amount of IL-1 present at either an mRNA or a protein level. 
Protein levels may be detected using Western blotting however using this 
technique, quantification of actual amounts is difficult. The real time reverse 
transcription polymerase chain reaction (real time RT-PCR) is the most 
sensitive method for the detection and quantification of low abundance mRNA 
from tissue samples. RT-PCR can be used to compare different levels of 
mRNA in different sample populations. Both these techniques can be used to 
determine whether IL-1 production is up regulated following cessation of IL-
1 ra therapy. 
6.1.3 Aims of this study 
The aim of this final section of the thesis was to determine whether early 
cessation of IL-1 ra therapy causes a rebound in IL-1 production, resulting in 
an exaggerated neointima response. 
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6.2 MATERIALS AND METHODS 
6.2.1 Quantification of protein and mRNA levels from porcine coronary 
arteries 
In order to determine the changes in levels of IL-1 induced by IL-1 ra at a 
molecular level, porcine coronary arteries were snap frozen into liquid 
nitrogen immediately after removal of the stent. Protein and RNA were 
extracted from this tissue and Real-Time peR and Western blotting used to 
determine the amount of IL-1 protein and mRNA present in each sample. 
6.2.2 Sample collection 
Two groups of animals underwent intracoronary stenting as described in 
section 5.2.3. One group received IL-1 ra for 14 days and wer~ killed at 17 
days and the other group received IL-1 ra for 17 days and were killed at 17 
days. The time-point of 17 days was chosen in order to allow 5 drug half 
" 
lives to pass and then to allow time for rebound IL-1 production to occur. The 
3 days without IL-1 ra was a best guess time-point. Animals that received a 
14-day infusion of IL-1 ra but that were culled at 17 days had their pumps 
removed at day 14. Those who received an infusion for the full 17 -days had 
new pumps inserted as before (see section 5.2.3). Animals in both these 
groups had a second 3.0mm stent inserted into distal vessel (in both the LAD 
and RCA). 
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At 17 -days, animals were killed as previously described (see section 5.2.4). 
The 3.0 mm stents were also explanted in situ but the stent was then removed 
from the artery and the tissue snap-frozen in vials of liquid nitrogen (for 
laboratory analysis such as real time PCR, see sections 6.2.2. and 6.2.13). 
6.2.3 Protein extraction from porcine coronary arteries 
Stored tissue was removed, weighed and ground to a fine powder under liquid 
nitrogen with a pestle and mortar. Powdered tissue was placed into a 
microfuge tube containing 3ml RIPA lysis buffer (see Appendix A.3) and 30111 
of 10mg/ml phenylmethylsulfonyl fluoride (PMSF) per gram of tissue. This 
was incubated on ice for 30mins and then centrifuged at 1 O,OOOg for 10 mins 
at 4°C. The pellet was discarded and centrifugation repeated until a clear 
lysate obtained. A MicroBCA™ protein assay (Pierce, Rockford, USA) was 
performed (see 2.10.2) to determine the protein concentration of each sample 
and samples were stored at -20°C until further use. 
6.2.4 Pierce MicroBCA™ protein assay 
This assay was used to determine the concentration of protein in each 
coronary artery. This allowed equal loading of protein onto a western blot in 
order for meaningful comparisons to be made. The working reagent was 
made up according to manufacturers instructions, mixing 25 parts reagent 
MA, 24 parts reagent MB and 1 part reagent MC. 
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The assay was performed in a 96-well plate and each plate read at 540nm at 
room temperature, using Labsystems Genesis V3.05 software. To each of 
the required wells on a 96-well plate, 150 /-ll of sample or standard and 150 /-ll 
of working reagent were added in order. The plate was covered and 
incubated at 37°C for 2 hours and cooled to room temperature before being 
read. The unknowns were compared with a known concentration of bovine 
serum albumin (ranging from 0.5 - 200/-lg/ml). 
6.2.5 Sodium Oodecyl Sulphate Polyacrylamide Gel Electrophoresis: 
SOS-PAGE 
This technique is used to detect proteins that have been transferred to a solid 
support (in this case a nitrocellulose membrane) from a polyacrylamide gel 
after electrophoretic separation. Proteins can be identified by the use of 
specific antibodies against the protein of interest. 
6.2.6 Acrylamide gel preparation 
A 15% acrylamide resolving gel was prepared and poured into the 'mighty 
small dual gel chamber' (Hoefer Scientific, San Francisco, USA), which was 
assembled according to manufacturers instructions. The ammonium 
persulphate (APS, SOH) and N,N,N,N'-tetramethylethylenediamine (TEMEO) 
were added last as these cause polymerisation of the gel. The resolving gel 
separated the proteins according to size. Proteins separate on size and not 
charge as the sodium dodecyl sulphate (SOS) present within the gel coats all 
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proteins, giving them the same charge. The gel was overlaid with water-
saturated butanol and allowed to polymerise for 45 mins. Once set, a 4% 
acrylamide stacking gel was prepared and poured on top of the resolving gel, 
the comb inserted to form sample wells and the gel allowed to polymerise (20 
mins). Details of gel preparation are shown in Appendix C. 
6.2.7 Sample loading and electrophoresis 
After the gel had polymerised, the comb was removed and the wells rinsed 
with distilled water. The plates were assembled in the 'mighty small II' 
running apparatus (Hoefer Scientific) and Tris-glycine-SDS buffer (25mM Tris! 
250mM glycine! 0.1 % SDS) was poured into the top and bottom reservoirs. 
Protein samples were thawed and an equal volume of 2X SDS protein sample 
loading buffer was added to each sample (see Appendix A.3). The protein 
sample-loading buffer contains beta-mercaptoethanol that keeps the proteins 
in a reduced state. For each blot, Rainbow markers (Amersham, UK) were 
used to enable correct protein size identification. All samples were heated at 
100°C for 5 mins to separate the proteins and stop them binding to each other 
or forming homodimers. 50jlg of protein was loaded per well. Positive 
controls were loaded onto each gel (200ng of carrier-free recombinant 
porcine-IL-1 alpha or beta, R&D Systems, UK). An Alpha tubulin Monoclonal 
antibody wa~ used at the detection stage as a loading control (product size 
50kDa). Each gel was run for 30-60 mins at 150 - 200V until the lowest 
marker had migrated to the bottom of the gel. 
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6.2.8 Semi-Dry Electro Blotting 
After electrophoresis, the gel was removed from the running apparatus and 
the stacking gel cut away. Each gel was then covered with 1-5mls of Towbin 
transfer buffer (39mM glycine/48mM Tris/0.037% SOS/20% methanol) to 
allow it to equilibrate and prevent it drying out. Each gel was measured and a 
suitably sized piece of nitroce"ulose membrane cut to exactly fit the gel. 6 
pieces of Whatman 3 filter paper was also cut to size and these along with the 
nitroce"ulose membrane were placed into Towbin transfer buffer to allow 
hydration. Transfer was carried out using the 'semi-phor' Hoefer Scientific 
semi dry blotter. The blot was assembled as follows: 3 pieces of Whatman 3 
filter paper, the nitroce"ulose membrane, the gel and then the remaining 3 
pieces of filter paper. Each blot was transferred for 90 mins at 5V at room 
temperature. After 90 mins, the blot was dismantled and labe"ed. 
6.2.9 Staining proteins 
The efficiency of protein transfer was established using Coumassie brilliant 
blue R250 (SOH, Poole, UK) to stain the gel and Ponceau S stain (SOH, 
Poole, UK) to stain the membrane. 
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6.2.10 Immunological Detection of Bound Proteins - Blocking Non-
Specific Binding Sites 
Non-specific binding sites on the membrane were blocked by placing it 
overnight in 5% (w/v) non-fat dried milk (Marvel) in Tris buffered saline, pH 7.6 
(TBS) at 4°C. 
6.2.11 Immunological Detection of Bound Proteins - Primary Antibody 
Incubation 
All primary antibodies were diluted in 10mls of blocking buffer containing 
0.05% (v/v) Tween-20 (Sigma, UK). The antibodies used were as follows: 
For IL-1 ~ detection, anti-porcineIL-1 ~ affinity purified goat IgG antibody (RnD 
systems, Minneapolis, USA) at a concentration of 0.2j.!g/ml and for IL-1 (l 
detection, anti-porcineIL-1 (l affinity purified goat IgG antibody (RnD systems, 
Minneapolis, USA) at a concentration of 0.2j.!g/ml. Hybridisation was carried 
out for 1 h on a rotating platform and each blot was then washed in 3X 
TBS/0.05%(v/v) Tween-20 for 5 mins. 
6.2.12 Immunological Detection of Bound Proteins - Secondary Antibody 
Incubation 
Secondary antibody incubation was carried out using anti-goat IgG directly 
conjugated to Horse Radish Peroxidase (HRP) at a dilution of 1:1000. 
Incubation was again for 1 h, followed by 3 x 1 Omin washes as above. 
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6.2.13 Immunological Detection of Bound Proteins· Visualisation of 
bound proteins 
The use of HRP results in the deposition of a coloured substrate on the 
membrane at the reaction site. Enhanced Chemiluminescence (ECL) was 
used to reveal the substrate and detection and detection was carried out 
using X-ray film. 
An ECL kit (Amersham Life Sciences) was used for the detection. 500Jllof 
each detection reagent provided by the kit were mixed together. The excess 
TBS was drained from the membrane and it was placed between clean pieces 
of plastic wrap. The mixed detection reagent was poured over the membrane 
surface and incubated for 1 minute. Excess reagent was drained off and the 
membrane was then exposed to X-ray film. Exposure times varied from 10 
minutes to 1 hour. Protein bands were then compared with the position of the 
markers to allow size determination. 
6.2.14 Extraction of RNA from arterial tissue 
RNA was extracted from porcine coronary arteries using an RNAeasy Mini Kit 
(Qiagen). It was vital that the RNA obtained was uncontaminated therefore; 
an extra DNAsin step was incorporated to ensure no genomic DNA 
contamination was present. 
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Stored porcine coronary artery (30mg, see section 6.2.2) was ground to a fine 
powder under liquid nitrogen with a pestle and mortar. The ground tissue was 
transferred into an RNase-free liquid nitrogen cooled, 2ml eppendorf. Any 
excess liquid nitrogen was allowed to evaporate and then 600lli of Buffer RL T 
added. The lysate was pi petted directly onto a QIAshredder spin column 
(Qiagen, UK) placed in a 2ml collection tube, and centrifuged for 2min at 
maximum speed. The lysate was removed and centrifuged for 3 min at 
maximum speed in a microcentrifuge. After centrifugation, the supernatant 
was transferred to a new microcentrifuge tube. 600lli of 70% ethanol was 
added to the cleared lysate and mixed immediately by pipetting. 700lli of this 
sample (including any precipitate that formed) was added to an RNeasy mini 
column placed in a 2ml collection tube. This was centrifuged for 15s at 
10,OOOrpm. Any flow-through was discarded and successive aliquots loaded 
onto the column and centrifuged as above. 350111 buffer RW1 was added to 
the column and the column was centrifuged for 15s at 1 O,OOOrpm to wash the 
column. The flow-through and collection tube were then discarded. 10111 of 
DNase I stock solution was added to 70111 Buffer RDD and mixed by gentle 
inversion. The DNase I mix (80IlI) was added directly onto the RNeasy silica-
gel membrane, and placed on benchtop for 15min. 350111 of buffer RW1 was 
added to the column and the column centrifuged at room temperature for 15 s 
at 10,OOOrpm. The flow through was discarded. The column was transferred 
onto a new 2ml collection tube, 500lli buffer RPE added to the column and the 
column centrifuged for 15s at 10,OOOrpm. A further 500lli of buffer RPE was 
added to the column that was centrifuged for 2min at 10,OOOrpm to dry the 
RNeasy silica-gel membrane. To elute the RNA, the column was transferred 
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to a new 1.5ml collection tube and 50J..L1 RNase free water pi petted directly 
onto the silica-gel membrane. This was centrifuged at rtp for 1 min at 
1 O,OOOrpm to elute the RNA. The elution step was then repeated with 30 J..L I 
RNase free water (see Appendix A.2). The amount of RNA present was 
determined using a spectrophotometer (see Appendix B). 
6.2.15 Extraction of RNA from porcine vascular smooth muscle cells 
This was done to obtain samples for use as a positive control. The method 
followed was as for 6.2.14 except that the media was removed from the flask 
of the cells and the cells washed with 10mls PBS. This was then removed 
and 600J..L1 of buffer RL T was added directly to the flask. The cells were 
scraped from the bottom of the flask with a plastic scraper and the solution 
pipetted directly onto the QIAshredder spin column. The method then 
proceeded as described in 6.2.14. 
6.2.16 Reverse transcription polymerase chain reaction (RT·PCR) 
RT-PCR was used to prepare cDNA for subsequent analysis. The first stage 
of RT-PCR is the synthesis of cDNA from the mRNA template. Once the 
cDNA had been formed, newly synthesized cDNA was amplified using 
specific pairs of primers designed to flank areas of genes of interest. 
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6.2.16.1 Reverse Transcription 
3J.!g total RNA was transcribed in a 20J.!1 volume. The reaction was carried out 
in RNAse-free disposable microfuge tubes and the reaction mixture 
contained, sterile water, 2~1; MgCI2, 4~1; 10X buffer, 2~1; dNTPs (1 mM each), 
8~1; random hexanucleotide primers, 1 ~I; Rnasin, 0.5~1 and avian 
myeloblastosis virus reverse transcriptase (AMV-RT), 1 ~I. All reagents were 
from Promega. 3~1 of RNA was added to 17~1 of sample mix. For the 
negative control, 3~1 of sterile water was used. A positive control was also 
used, in the case of these experiments, RNA extracted from THP1 cells and 
porcine smooth muscle cells that had been stimulated with LPS (1 ng/ml) were 
used. PCR was carried out on the PTC-200 Peltier Thermal Cycler (M J 
research). The PCR was carried out under the following conditions: 
Step 
1 
2 
3 
4 
5 
6.2.16.2 
Temperature (OC) 
23 
42 
99 
4 
15 
Time (min) ; 
10 
pO 
5 
10 
00 
Polymerase Chain Reaction (PCR) . 
Newly synthesized cDNA was amplified using specific primers for porcine IL-1 
alpha, beta and IL-1 receptor antagonist. 5J.!1 of cDNA was typically used for 
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each reaction. In all of these experiments, ~-actin was used as a loading 
control as it is abundant in porcine tissue. All primers were designed and 
used as a 15/-lM stock solution. All samples to be used were defrosted. All 
RNA underwent RT-PCR (see 2.10.6.1) to obtain the cDNA. A negative 
control was performed for all experiments and sterile water was used. The 
sample mix buffer was made up as follows: Sterile water, 18.251J1; 10X buffer, 
2.51J1; dNTPs, 21J1; primer 1, 0.51J1; primer 2, 0.51J1; Taq Polymerase, 0.251J1; 
and MgCI2, 11J1. The annealing temperature used for the peR depended upon 
the primer pairs used but an example of a typical PCR program is shown: 
Step Temperature (DC) Time (min) 
1 94 2 (initial cDNA:mRNA denaturation) 
2 94 1 (denatures cDNA) 
3 53-60 1 (annealing of primers) 
4 72 1 (DNA extension) : 
5 return to step 2 for cycling (repeated 29 - 35 times) 
6 72 5 (final extension) 
7 4 10 
8 15 00 (holding temperature) 
6.2.17 PCR primer design 
Primers for ~-actin and porcine IL-1 ~ were available for use within the 
department. The sequences for the primers used to isolate porcine IL-1 (l 
were taken from Spagnuolo-Weaver et al [123]: The sequence for porcine IL-
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1 ra is known and the computer program MacVector was used to design 
primer pairs for isolation of IL-1 ra, thereby avoiding adverse structural 
properties such as 'hairpin loops'. 
Primer Information: 
Table 1 Primers constructed for PCR 
Target Accession Primer sequence (5' - 3') Product 
Number size (bp) 
IL-1 a. X52731 F:ACAGAAGTGAAGATGGCCAAAGTC 385 
-
R:TCATGTTGCTCTGGAAGCTGTATG 
IL-1~ M86725 F:TCATCGTGGCAGTGGAGAAGC 619 
R: TCTGGGTATGGCTTTCCTT AG 
IL-1ra L38849 F:CTTTCCTCCTTTTCCTGTTCCAC 471 
R:TGGTGACCTTGACGGCTGC 
~-actin U07786 F:CTCGGTCAGGATCTTCATGAGG 324 
R:TTCTACAATGAGCTGCGTGTGG 
Primers were constructed by OswellEurogentec SA (Oswel, Hampshire, UK). 
They were received in dry pellet form and resuspended in sterile water. 
Purified primer concentration was calculated using a spectrophotometer at 
260nm (RNA ~g/~1 = A260 x dilution factor x 0.04). Despite numerous attempts 
with different primer pairs (an example of one primer set tried is given above) 
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and different annealing temperatures, no successful amplification of porcine 
IL-1 ra was achieved. 
6.2.18 Agarose Gel Electrophoresis 
Once complete, the products were run on a 2% agarose gel to confirm that 
amplification of the correct sized product had occurred. Powdered agarose 
(Promega) was melted in 1 x TAE buffer (0.04M Tris-acetate/0.001 M EDTA) 
in a microwave for 2 mins. 10mg/ml ethidium bromide (Sigma) was added to 
the gel to give a final concentration of 0.5Jlg/ml. The liquid gel was poured 
into a gel tray and allowed to cool. 15JlI of peR product was used for 
electrophoresis along with DNA markers (Promega) of known molecular sizes 
to allow size determination. For these experiments, PhiX174 DNA HAE 
marker (Promega, UK) was used at a concentration of 1IJg/IJI for all gels. 5JlI 
of loading dye (type IV loading dye - 40% (w/v) sucrose in sterile water with 
10 Jlg bromophenol blue) was added to each sample. Electrophoresis was 
carried out in 1 x T AE buffer at 9000 for 20 - 60 mins. The negatively charged 
DNA migrated towards to anode and was separated on the basis of size. 
Visualisation of PCR products was carried out under UV light. 
6.2.19 TA Cloning into Plasmid Vectors 
TA Cloning provides a means of inserting a PCR product into a plasmid 
vector. Taq polymerase has a nontemplate-dependent activity that adds a 
single deoxyadenosine (A) to the 3' end of amplified PCR products. The 
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vector contains single 3' T-overhangs at its insertion site and therefore, the 3' 
A-overhangs of the PCR produce can be inserted into the vector. Fresh peR 
products were used for all ligation experiments. 
6.2.20 Transformation of DNA into bacteria 
TOP 10 competent cells (Promega), an E. Coli bacterial strain, were used for 
all transformations. Transformation was according to manufacturers protocol. 
Briefly, 200~1 cells were mixed with 1-2~1 plasmid DNA. The cells were 
incubated on ice for 30 minutes, heat shocked at 42°C for 40 seconds and 
then incubated on ice for a further 2 minutes. 900j .. tI of Luria-Bertani (LB) 
medium was added to each vial of cells at they were incubated at 37°C for 60 
minutes in a shaking incubator. 1 OO~I of each mixture was plated onto LB 
agar plates and incubated in a shaking incubator at 37°C overnight. 
i 
Transformants were selected by antibiotic selection. LB agar plates were 
prepared containing, 25~g/ml of Kanamycin. 
Blue/white colour screening was used for selection. The plasmid vector will 
produce p-galactosidase by a-complementation when transformed into 
bacteria after exposure to IPTG (P-D-isopropyl-thiogalactopyranoside). a-
complementation is a process by which a functional p-galactosidase (LacZ) 
gene is generated when LacZ a-peptide (provided by the vector) 
complements the co fragment of LacZ (provided by the bacteria). In the. 
presence of X-gal (5-bromo-4-chloro-3-indoyl-p-galactopyranoside), cells with 
a plasmid but no DNA insert exhibit a blue colour and those with a DNA insert 
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exhibit a white colour (the LacZ gene is interrupted and a-complementation 
prevented). 
6.2.21 Cloning peR products 
The reaction was set up according to manufacturers instructions. Briefly, the 
ligation reaction was as follows: 5111 sterile water, 1111 10 X reaction buffer, 2111 
pCR®2.1 vector, 1 or 2111 PCR product, 1111 T 4 DNA ligase (The total volume 
of the reaction was 10111 so where 2111 of PCR product was used, the volume 
of sterile water was reduced to 4111). The ligation reaction was incubated at 
14°C overnight. The ligated vector was transformed into TA cloning one-shot 
competent cells (TOP 10 E.Coli). One vial of cells was used per ligation 
reaction. For each reaction, 1,2 and 3111 of ligation reaction was mixed gently 
with the cells. The cells were incubated on ice for 30 minutes, heat shocked 
at 42°C for 40 seconds and incubated on ice for 2 minutes. 900111 of SOC 
medium was added to each vial of cells and incubated at 37°C for 60 minutes 
with agitation. During this time, 25111 of X-Gal was spread onto previously 
poured LB agar plates containing Kanamycin. After incubation, 100111 of 
transformed cells were spread over each agar plates (one plate per 
transformation) and incubated overnight at 37°C. White colonies were then 
chosen for plasmid isolation as they contained the cloned PCR product. 
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6.2.22 Plasmid DNA Miniprep 
Once appropriate clones had been chosen, single colonies were used to 
inoculate 5mls of LB medium containing Kanamycin. This was then incubated 
overnight in a 15ml tube in a shaking incubator at 37°C. The protocol used for 
the Miniprep was the QIAprep Spin Miniprep Kit. 
6.2.22.1 The QIAprep Spin Miniprep Kit 
The protocol was followed according to the manufacturers instructions. In 
brief, 1 ml of each overnight bacterial culture was pelleted in a microfuge tube 
by centrifugation at 8000rpm for 5mins. The supernatant was removed and 
the pellet resuspended in 250J..lI Buffer P1. To this, 250J..lI Buffer P2 was 
added and the microfuge tube gently inverted 4 - 6 times to mix. 350J..lI Buffer 
) 
N3 was added and the tube inverted immediately 4 - 6 time~. This was then 
centrifuged at room temperature for 10min at 13,000rpm. The supernatants 
were transferred to the QIAprep column by decanting or pipetting. These 
were centrifuged for 60sec at 13,000rpm and the follow through discarded. 
The column was washed by adding 0.5ml Buffer PB and centrifuging for 
60sec (13,000rpm). A further wash was then performed by adding 0.75ml 
Buffer PE and centrifuging for 60 sec (13,000rpm). The follow through was 
again discarded and residual wash buffer removed by a further 60 sec 
centrifugation (13,000rpm). The QIAprep column was placed into a clean 
1.5ml microcentrifuge tube. To elute DNA, 50J..lI of Buffer EB (10mM Tris.Hel, 
pH8.5) was added to each column. The column allowed to stand for 1 min and 
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then centrifuged for 1 min (13,OOOrpm). The DNA sample obtained was then 
digested and analysed by agarose gel electrophoresis. The DNA was then 
stored at -20°C until further use. Details of the buffers used are given in 
Appendix A.4. 
6.2.22.2 Restriction Digest of Plasmid 
This was performed to ensure that the plasmid had incorporated the gene of 
interest. For the pCR2.1 vector, the Eco RI restriction enzyme cleaves either 
side of the insert site and therefore this enzyme was used for all digests. The 
reaction was set up as follows: 5JlI nuclease free water, 2JlI multi-core 
restriction enzyme 10X buffer; 2JlI Acetylated bovine serum albumin (1 mg/ml); 
10JlI DNA sample; 1 JlI restriction enzyme (Eco RI). The reaction mixture was 
incubated at 37°C for 4h at 37°C. Once complete, 5JlI of loading dye was 
added to each sample and the samples electrophoresed on a 2% (w/v) 
agarose gel. 
6.2.23 Plasmid DNA Maxipreps 
Maxipreps are used to isolate large quantities of DNA. The sample that had 
the brightest band on the gel after restriction digest was used for the Maxiprep 
procedure. Many different kit and non-kit based methods are available, for 
this section of work the EndoFree Plasmid Maxi Protocol (Qiagen) was used. 
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6.2.23.1 EndoFree Plasmid Maxi Protocol 
This Maxiprep kit allows the isolation of endotoxin free plasmid DNA by using 
a Qiagen resin packed into a Qiagen tip. It allows the binding of plasmid DNA 
to an anion exchange resin. Proteins and RNA are removed and the DNA is 
eluted and concentrated and purified by iso-propanol precipitation. The 
protocol was carried out according to the manufacturers instructions. 
In brief, 2001-11 of sample was added to 200ml of LB broth (containing 2Sllg/ml 
Kanamycin) and placed in shaking incubator at 37°C overnight. The bacterial 
cells were harvested by centrifugation at 6000-x g for 1Smin at 4°C, the 
supernatant discarded and the pellet resuspended in 10ml Buffer P1. The 
mixture was transferred into a SOml falcon tube. 10ml Buffer P2 was added 
and mixed gently and thoroughly by inverting 4 - 6 times. This was then 
incubated at room temperature for S mins. 10ml of chilled Buffer P3 was 
added to the lysate, and mixed immediately by inverting 4 - 6 times. The 
lysate was poured into the barrel of the QIAfilter Cartridge and incubated at 
room temperature for 10mins.The cap from the outer nozzle was removed 
and the plunger inserted. The lysate was filtered into a SOml falcon tube. 
2.Sml of Buffer ER was added to the filtered lysate and mixed by inverting the 
tube 10 times. This was incubated on ice for 30 min. A QIAGEN-tip SOO was 
equilibrated by applying 10 ml Buffer QBT and the column allowed to empty 
by gravity flow. The filtered lysate was added to the QIAGEN tip and allowed 
to enter the resin by gravity flow. The tip was washed with 2X 30ml Buffer 
QC. The DNA was then eluted with 1Sml Buffer QN into a glass endotoxin-
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free tube and precipitated by adding 10.5ml room temperature isopropanol, it 
was then mixed and centrifuged immediately at 15,000g for 30 min at 4°C. 
The supernatant was decanted and the DNA pellet washed with 5ml of 
endotoxin-free room temperature 70% ethanol and centrifuge at 15,000g for 
10 min. The supernatant was the decanted taking care not to disturb the 
pellet. The pellet was then air-dried for 5-10 min and the DNA then re-
dissolved in 250J,J1 of endotoxin-free Buffer TE. Details of the buffers are 
given in Appendix A.4 
The yield of DNA was determined by spectrophotometry and run on a 2% 
(w/v) agarose gel. A restriction digest (see 2.13.4) was set up to confirm 
presence of the insert. 
6.2.24 Analysis of mRNA content of tissue using the Real· Time 
Quantitative reverse transcription polymerase chain reaction (RT.PCR) 
Reverse transcription polymerase chain reaction is the most sensitive method 
available for the detection and quantification of low-abundance mRNA. This 
technique enables the detection of small differences in gene expression 
between tissues. In this work, it was used to determine whether differences in 
the level of IL-1 a and IL-1 ~ levels in the vessel wall following balloon 
angioplasty or stenting could be identified. Following RT-PCR, two 
quantification strategies, either absolute or relative can be employed. In 
absolute quantification, the absolute mRNA copy number per reaction is 
determined by comparison with external calibration curves. This allows 
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comparisons between reactions carried out on different days or with different 
reagents. The relative expression is based on the expression ratio of a target 
gene to a reference gene and enables investigation of physiological changes 
in gene expression levels. Relative expression explains trends but results will 
depend upon the reference gene and the normalization procedure used. One 
draw back of quantification using relative expression ratios is that it only 
allows comparison of one sample with the reference gene. A new software 
tool REST© (relative expression software tool), has been developed that 
allows for comparison of two sample groups, with up to 16 data points in the 
sample and control group, and tests the group differences for significance with 
a newly developed randomisation test [124]. 
Total RNA was extracted using the commercially available RNeasy mini kit 
(Qiagen) (see 6.2.14). In each case on column DNA digestion was carried out 
using the RNase-free DNase set (Qiagen) to prevent carryover of 
contaminating genomic DNA to the PCR reaction. Concentration of total RNA 
was determined by measuring the absorbance at 260nm in a 
spectrophotometer. For each sample, 500ng total RNA was reverse 
transcribed to cDNA using the commercially available Superscript III kit 
(Invitrogen) with random hexamers as primers according to the manufacturers 
instructions. For each sample, an 'RT minus' control reaction was carried out 
in parallel. cDNA /'RT minus' samples were then diluted 1: 10 with water and 
stored at -20 °C for later use. Primers were designed for the genes of interest 
and housekeeping genes using the commercially available molecular biology 
program MacVector (version 7.1.1). Primer parameters were as follows: 
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product size 75-150 base pairs; primer length 1S-30 base pairs; primer GC 
content 30-70 % and primer Tm 55-SO 0 C (Accession numbers: Pig IL-1 
alpha, X52731; Pig IL-1 beta, M86725; Human 18SrRNA, K03432). There is 
only a partial sequence in the database for Pig 18SrRNA. However such is 
the homology between 18SrRNA sequences across species that primers 
designed to the human 1SSrRNA sequence were found to work well on Pig 
total RNA. 
Primer sequences: 
Table 2 Primers used for Real-Time PCR 
Target Accession Primer sequence (5' - 3') Product 
number size 
; 
I 
(bp) 
Pig IL-1a X52731 F:CCTCT AAGACATCCAGGCT AAACTTC 385 
R:CTTCCAGGTCGTCATCGGTG 
Pig IL-1P M86725 F:TGAAGAATCCCTCCTCCCAGG 617 
R:GGCATCACAGACAAAGTCATCATTG 
Human K03432 F:ACACGGACAGGA TTGACAGA TTGATAG 122 
1SSrRNA R:ATGCCAGAGTCTCGTTCGTTATCG 
Primers were synthesized and HPLC purified commercially (Sigma-Genosys). 
All PCR reactions were carried out in an iCycler (Bio-Rad) using SYBR Green 
I (Molecular Probes) as the fluorescent dye. Triplicate 20 ~I reactions were 
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carried out for each sample using the commercially available iQ Supermix 
(Bio-Rad). Thermal cycling parameters were as follows: 
Step Temperature (OC) Time (sec) 
1 95°C 180 (Hotstart) 
2 95°C 30 (Denaturation) 
3 repeat step 2 for 40 cycles 
4 60 °C 30 (Annealing/Extension) 
5 95°C 30 (Melt curve analysis) 
6 50°C 30 
7 50 °C 10 
8 repeat step 7 90 cycles and add 0.5 °C every 10 seconds 
In order to validate primer sets for amplification efficiency and specificity prior 
to use on biological samples, genes of interest were subcloned into a plasmid 
vector according to standard molecular bio.,logical techniques; pCR 2.1 
(Invitrogen) for Pig IL-1 alpha and beta (see 6.2.20) and pGEM-T Easy 
(Promega) for Human 18SrRNA. Restriction digests and direct sequencing in 
each case confirmed successful subcloning. Plasmids were linearised by the 
use of a single cutting restriction enzyme ensuring the single site was outside 
the subcloned region. Linearised plasmids were purified using the 
commercially available PCR purification kit (Qiagen) and a ten fold dilution 
series was generated. The specific primer sets were tested against the ten 
fold dilution series of the corresponding plasmid and by plotting the threshold 
cycle (Ct) against the log of the initial starting concentration a standard curve 
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was generated whose slope gives the amplification efficiency by the equation: 
E (%) = (10(-1/sI0pe)_1) X 100. 
All 3 primer sets gave a single peak on melt curve analysis implying that only 
one product was being amplified and thereby confirming the specificity of the 
reaction. Amplification efficiencies were as follows: Pig IL-1 alpha E = 
93.1 % (correlation coefficient = 0.998); Pig IL-1 beta E = 101.7% (correlation 
coefficient = 0.998); Human 18SrRNA E = 95.0% (correlation coefficient = 
1.000). Having validated the. specific primer sets on plasmid cDNA they were 
then used on tissue cDNA samples to generate data. Each run contained an 
RT minus control for each sample and a no template control for each primer 
set. Data was collected as the mean of the cycle threshold (Ct) for triplicate 
reactions on each sample +/- S.E.M. 
i 
6.2.25 Quantitative Real time polymerase chain reaction 
These experiments were performed to see if changes in IL-1 mRNA levels 
could explain the 'catch-up' phenomenon seen following cessation of the IL-
1 ra treatment. Tissue was obtained following stenting; RNA extracted and off 
IL-1a and IL-1f3levels in the vessel wall determined using quantitative RT-
peR. IL-1 ra treatment was compared with vehicle treatment following 14-day 
and 28-day infusions and also a further two groups of animals were 
compared, one group that received IL-1 ra for 14-days and was sacrificed at 
17 days and the other that received IL-1 ra for the full 17-days. Quantification 
was carried out relative to an untreated control sample and normalized to 
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18SrRNA levels as previously described using the equation: 2· MCt where ~et 
= et (target gene) - et (housekeeping gene) and Met = ~et (treated sample) 
- ~et (untreated sample). Statistical analysis was performed using REST© 
software. 
i 
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6.3 RESULTS 
6.3.1 Protein assay 
The first approach to quantify IL-1 levels in the vessel wall after stenting used 
Western Blotting. A protein assay was performed to ensure that equal 
concentrations of protein were loaded into each well for each Western blot. 
This enabled meaningful comparisons to be made between samples. Figure 
44 shows an example of a Bovine serum albumin standard curve obtained. 
The total concentration of protein in each sample was then determined from 
the standard curve and a known amount of protein loaded into each well for 
the Western blot. 
6.3.2 Detection of protein levels - Western blots 
Western blotting was performed to see if a difference in protein levels 
between the animals that received IL-1ra for 14-days and were killed at 17-
days and those that received an IL-1 ra infusion for the full 17-days could be 
detected. Figure 45a (blot for IL-1 13) is an example of a blot obtained. As it 
can be seen, no IL-113 protein was detected in any of the samples analysed. 
In all cases, the positive control alpha tubulin was present (see Figure 45b). 
Blots were performed, using the protein samples extracted from all the 
animals studied, unfortunately, despite good protein yields, and loading of 
50jJg total protein on the gel, no IL-1 was detected. 
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Figure 44 An example of a standard curve obtained using the Pierce 
MicroBCA™ protein assay 
Protein standards were bovine serum albumin. 
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a 
17kDa • 
Il-1~ 
Sample M + 1 2 3 4 5 6 7 8 
b 
55kDa • 
a-tubulin 
Sample M 1 2 3 4 5 6 7 8 
Figure 45 Independent Western blots for (a) Il-1~, 17kDa and (b) 
loading control a-tubulin, 55kDa (each blot is representative of n=3) 
M represents molecular weight markers not clearly visible after reproduction 
but marked on the left hand side of the blot. In (a) lane + is porcine 
recombinant IL-1~ (100ng/ml), lanes 1 - 7 are samples (JG767 LAD, JG767 
RCA, JG768 LAD, JG 768 RCA, JG769 LAD, JG769 RCA, JG770 LAD). In 
(b) Lane 8 is the positive control, lanes 1 - 7 are samples (JG767 LAD, 
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JG767 RCA, JG768 LAD, JG 768 RCA, JG769 LAD, JG769 RCA, JG770 
LAD), where JG767 and JG769 were 14d infusion, 17d harvest and JG768 
and 770 were 17d infusion, 17d harvest). 
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6.3.3 RT-PCR, cDNA amplification and TA cloning of porcine IL-1alpha 
In order to validate primer sets for amplification efficiency and specificity prior 
to use on biological samples, segments of the genes of interest were 
subcJoned into a plasmid vector according to standard molecular biological 
techniques; pCR 2.1 (Invitrogen) for Pig IL-1 alpha and beta (see 6.2.21) and 
pGEM-T Easy (Promega) for Human 18SrRNA. Restriction digests and direct 
sequencing in each case confirmed successful subcloning. Plasmids were 
linearised by the use of a single cutting restriction enzyme ensuring the single 
site was outside the subcloned region. Porcine IL-1 ~ had previously been 
subcloned and was available for use within the department. Figure 46 shows 
the amplification of porcine IL-1 a mRNA from porcine vascular smooth muscle 
cells. Once the cDNA had been isolated, a miniprep was used to amplify the 
gene (Figure 47a). The gene of interest was then sent for sequencing. Once 
i 
this had confirmed successful cloning, a maxiprep was performed to obtain 
large amounts of the gene of interest for use in the Real-Time PCR 
<, 
experiments (Figure 4 7b). 
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324bp • 
a-actin 
Lane 1 2 3 4 5 6 7 8 9 10 
Figure 46 Amplification of porcine IL-1 a from porcine vascular 
smooth muscle cells (VSMC) 
Lane 1 shows the marker. Lanes 2,3 and 5 show the loading controls (in this 
case p-actin, product size 324bp) extracted from porcine coronary artery 
(lanes 2 and 3) and porcine VSMC (lane 5). The negative controls are shown 
in lanes 4 and 7. When specific IL-1 a primers are used, IL-1 a is successfully 
isolated from porcine unstimulated VSMC (lane 10, product size 385bp) but 
not from porcine coronary arteries (Lanes 8 and 9). Lane 6 was left blank. 
2 4 
a 
385bp -. 
Sample M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
b 
385bp -. 
Sample M 1 2 3 
Figure 47 Minipreps of IL-1 a cDNA from porcine VSMCs 
(a) Amplification of IL-1a cDNA is shown in even lanes and contro l 
amplifications in odd lanes. There is good amplification from all cultures apart 
from lane 14. From these, the 2 brightest bands were chosen, in this case 
from lanes 8 and 10 and these clones were then used for inoculation of the 
maxiprep culture. (b) Restriction digest of the maxiprep with EcoR1. Lane 1, 
no digest, lanes 2 and 3 show EcoR1 restriction and an insert at 385bp. 
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6.3.4 Extraction of RNA from porcine coronary arteries 
RNA was extracted from each piece of c~ronary artery as described in 6.2.13. 
Concentration of total RNA was determined by measuring the absorbance at 
260nm in a spectrophotometer. Values obtained ranged from 4 - 300J,lg/ml. 
Once extracted, the RNA was stored at -20°C until further use. 
6.3.5 Real-time peR 
To provide an explanation for the increase in neointima seen following 
cessation of IL-1 ra therapy, the amount of IL-1 ex and ~ mRNA in porcine 
coronary vessels was determined by quantitative RT-PCR. Each sample was 
run in triplicate and the mean of the values obtained used for comparisons 
between groups. Comparison was made using REST©. 18srRNA was 
chosen as the housekeeping gene. As SyBr green is a non-specific 
fluorescent dye, i.e. binds to all DNA, specificity of the primers was confirmed 
by melt-curve analysis (Figure 48). Having confirmed that for all primers, a 
single product was obtained, the samples were then analysed. Using this 
technique, no difference in the IL-1 ex or IL-113 levels could be detected 
between animals implying that at the time-point studied, early cessation of IL-
1 ra therapy had no significant effect on the total levels of IL-1 ex and IL-113 
(mean expression ratios 1.966 and 1.307, p = 0.41 and p = 0.67 respectively, 
see Figure 49). 
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Figure 48 Melt curves generated during qRTPCR 
(a) p1L-1 , (b) p1L-1 p, (c) h18srRNA. Note: one single pe R species (ie 1 
peak) in each case. 
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Figure 49 Box and whisker plots showing the effect of IL·1 ra therapy 
on vessel wall (a) IL·1a mRNA and (b) IL·1 ~ mRNA levels 
Total IL-1 levels in the vessel wall were determined by quantitative RT-PCR 
and plotted as cycle number (minus 18SrRNA (housekeeping gene». 
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6.4 DISCUSSION 
6.4.1 Summary of findings 
When IL-1ra therapy was discontinued at 14 days, there was a rebound in 
neointima formation following stenting. In order to try and explain this, it was 
hypothesised that the IL-1 ra infusion could be not only inhibiting IL-1 
signalling but also inhibiting IL-1 production, and that discontinuation of the IL-
1 ra around 14-days was associated with a rebound production of IL-1. 
Analysis of protein expression and mRNA levels for IL-1 a and ~ 3 days after 
IL-1 ra discontinuation at 14-days (in this case by removal of the pumps) did 
-
not indicate any such increased levels. The cause of the rebound production 
in the neointima is still under investigation. 
6.4.2 Detection of protein levels - Western Blotting 
No increase in IL-1 at the protein level was detected by Western blotting. 
There are several possible explanations for this. First, IL-1 expression in the 
vessel wall is likely to be constitutively low. Levels within the vessel wall may 
be below the lowest level of detection even when up-regulated. Second, 
following death, it takes an unavoidable amount of time (at least 10 mins) to 
explant the heart and remove the vessel and stent. Due to this, protein 
degradation before snap freezing has to be considered as a potential source 
of sample loss. Third, IL-1 release and/or altered processing mechanisms 
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may result in cytokine loss into the circulation or alterations in protein 
structure that the current analysis systems fail to detect. 
6.4.3 Detection of mRNA 
The time-point of three days post cessation of IL-1 ra therapy was chosen to 
allow five drug half-lives to pass and then to allow 24 hours for rebound 
production of IL-1 to occur. No differences in levels of either IL-1 a or IL-1 ~ 
mRNA at the time-points studied were detected. IL-1 mRNA is known to be 
unstable and it is likely that due to sample processing, some IL-1 mRNA 
degraded hence any differences in levels could not be detected. It is also 
worth considering that the wrong time-point may have been studied and that 
either an earlier or later time-point should have been considered. 
Unfortunately, this model does not easily allow for sampling a! different time-
points. Another reason for failure to detect a difference in mRNAs is that 
perhaps the focus should be on other cytokine or processing molecules e.g. 
Caspase-1. In addition, molecules further downstream in the signalling 
cascade such as IL-6 or IL-8 may be up-regulated along with up-stream 
molecules such as PDGF. 
6.4.4 REST© software analysis 
Relative expression is used in the analysis of results obtained in real-time 
peR. The expression of the target gene is standardised by a non-regulated 
reference gene. The relative expression software tool (REST©) is novel in 
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that it allows a comparison of two groups, with up to 16 samples in both the 
sample and control group and up to four target genes. The mathematical 
model used is based upon the PCR efficiencies (E) and the mean crossing 
point deviation between the sample and control group (~CP). The expression 
ratio obtained is then tested for significance by a randomisation test. 
6.5 Conclusions and future directions 
The data presented so far does not support the hypothesis that the increase 
in neointima formation following cessation of IL-1 ra therapy is caused by a 
rebound increase in IL-1 production. Unfortunately the porcine model does 
not allow for the sampling of multiple time-points in multiple animals and 
therefore, the possibility that IL-1 mRNA would have been altered at earlier or 
later times following IL-1 ra discontinuation cannot be excluded. Further work 
is needed to determine the molecular basis of the catch-up seen. 
Unfortunately, real-time PCR is the most sensitive technique available to 
detect changes in mRNA levels. If the sample degradation is the cause of our 
inability to see significant changes in IL-1 mRNA levels then studying different 
" time-points using the same technique are unlikely to be successful. An earlier 
(18h) or later time-point of 48-hours will be studied and we shall also look for 
the up-regulation of other molecules such as IL-1 signalling intermediates IL-6 
or PDGF to see if any difference in expression can be detected. 
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CHAPTER 7 
CONCLUSIONS AND FUTURE WORK 
This work has shown that antagonism of IL-1 by IL-1 ra inhibits neointima 
formation after coronary artery injury and stenting in a porcine model. In the 
case of PTCA, IL-1 ra resulted in a 23% decrease in neointima area, 
independent of the length of IL-1 ra therapy. In the case of stenting, IL-1 ra 
inhibited neointima formation for the duration of the infusion, but after 
cessation of the infusion around 14 days, there was a 'catch-up' phenomenon, 
with a 34% larger neointima in IL-1 ra treated arteries than vehicle. The 
mechanism for this difference in effect of IL-1 ra has yet to be explained. 
IL-1 ra is a large protein with inhibitory properties upon the Type 1 IL-1 
receptor. Agonistic IL-1 cytokines signal inflammatory events via this 
receptor, which is blocked by IL-1 ra. In general terms, IL-1 ra blocks new IL-1 
signalling events over the Type 1 receptor, rather than acting by competitive 
" 
displacement binding. Blockade of the Type 1 IL-1 receptor is the only known 
anti-inflammatory property of IL-1 ra [125]. Thus, the data presented here, 
which show a powerful modulatory effect upon the neointimal response to 
injury, are conclusive evidence that IL-1 has a critical role in this process. 
IL-1, together with TNF and complement, in a variety of complex inflammatory 
models, processes and diseases are viewed as having an apical position in 
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the signalling cascade that produce the multiplicity of effects seen in these 
situations. This apical position indicates not only the relative importance of 
these agents (Le. lack of redundancy) but is also proven when they are 
antagonised. A notable example would be the inhibition of TNFa and IL-1 in 
rheumatoid arthritis [126]. The results reported here suggest that IL-1 may 
have a crucial position in the arterial response to injury. 
There are multiple potential sources of IL-1 at the time of arterial injury. 
Adherent platelets may produce IL-1, as well as the recruited inflammatory 
cells. In addition endothelial cells, which re-grow and cover the site of injury 
may also produce IL-1. IL-1 has many inflammatory effects upon endothelial 
cells and vascular smooth muscle cells, plausibly associated with neointima 
formation and notable amongst these is the autocrine induction of PDGF by 
vascular smooth muscle cells [3]. 
As already discussed, the pig is a commonly used model for studies such as 
these however; a recurring criticism of such studies concerns the validity of 
animal models. Animal models contribute significantly to the assessment of 
safety of a stentldrug combination, but efficacy is more contentious. These 
models lack atherosclerosis, and rely upon de novo growth of neointima 
arising from intervention in an undiseased artery. In their favour, microscopic 
examination of this neointima is reassuring - it is histologically 
indistinguishable from that seen in human restenotic tissue obtained at 
necropsy or atherectomy. Another disadvantage with animal models is that 
they employ juvenile subjects which grow significantly during the course of the 
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experiment under the influence of a growth hormone milieu which is likely to 
be significantly different from that seen in a middle aged human subject. 
Finally, of course, are the inevitable genetic differences. Here, the pig model 
scores highly because of the well-known similarities between the pig genetic 
constitution and man. A useful paradigm is rapamycin. When rapamycin-
loaded stents were tested in a porcine coronary artery model, the effect upon 
in-stent neointima formation was not as dramatic as the results from the first 
human studies where restenosis was reduced to 0%. The magnitude of 
inhibition of neointima response found in our studies is in keeping with that 
study and therefore may indicate an important and potentially useful clinical 
effect. 
In the clinical setting, it is not realistic to administer IL-1 ra by continuous 
subcutaneous infusion. This would necessitate long inpatient hospital stays 
I 
and would be uncomfortable and difficult for patients to manage. In the 
animal study performed, the IL-1 ra was delivered using mini-osmotic pumps. 
Complications attributed to subcutaneous administration of other fluids, 
include tissue necrosis at the infusion site, cellulitis, abscess formation and 
even gas gangrene. Although these complications are rare nowadays 
(because of improved aseptic techniques), they remain a potential problem 
with prolonged infusion. In reality, the administration of continued IL-1 ra for 
treatment of instent restenosis will require the development of a stent-based 
delivery system. The intravenous bolus of IL-1 ra administered at the start of 
all of the experiments performed in this work could still be administered to a 
patient with an acute coronary syndrome on arrival to hospital, either 
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immediately before transfer or on arrival to the catheter laboratory. However, 
before IL-1 ra on a stent can be considered we need to look carefully at 
mechanism of any rebound effect. It may be that the timing is such that IL-1 ra 
is required for months. 
The strength of using a coated stent as the carrier for an anti-restenosis agent 
is the ability to achieve a high local concentration of potent therapeutic, 
exactly where it is required, whilst using a tiny total quantity of drug, thereby 
avoiding any systemic side effects. When designing a drug-eluting stent, the 
polymer to which the drug is attached is of paramount importance. In order to 
achieve local delivery, a drug must be loaded onto a delivery platform that 
allows its controlled release. The polymer must, amongst other properties, 
have the capacity to allow drug uptake and release, be inert to prevent an 
adverse reaction and be able to withstand the rigours of sterili~ation and stent 
deployment. Several different agents have already been shown to fulfil these 
and other criteria, including, phosphorylcholine (used for dexamethasone 
elution) and chondroitin sulfate and gelatin (used for paclitaxel elution). 
The therapeutic implications of these results are at least two fold. First, there 
can be little doubt that IL-1 ra is a potential therapeutic agent for the treatment 
of proliferative vascular responses. The potential application of such an anti-
inflammatory treatment is clearly of some excitement in the context of 
coronary artery disease, which is now viewed as an inflammatory process 
both in terms of atherogenesis and mechanisms of disease presentation. 
Secondly, these results suggest that examination of the duration of such 
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therapy will be crucial for its success. The duration of the healing response 
and neointima following stent implantation is still imprecisely understood but 
clinical studies as well as experience suggest that the process may continue 
up to 9 months [69]. We can only speculate upon what the duration of IL-1 ra 
would need to be for clinical utility, but by analogy with cytostatic stent based 
delivery, many weeks may be needed. 
To use IL-1 ra as a treatment strategy for humans, further work must be 
performed to determine the mechanism of catch up seen following cessation 
of therapy. Unlike TNF-a or other pro-inflammatory cytokines, the IL-1 
signalling pathway is complex and regulated at many levels. Pro-IL-1 ~ is 
released from vascular cells via an as yet largely unknown, possibly P2X7 
dependent mechanism. On its release it is cleaved by Caspase-1 into mature 
IL-1 ~ and then signals via the type-1 receptor. Signalling via the receptor 
i 
leads to up-regulation of other pro-inflammatory cytokines. This work has 
only investigated up-regulation of IL-1 a and IL-1 ~ in the vessel wall. As no 
difference has been seen, further work will focus on other RNAs, for example, 
endogenous porcine IL-1 ra or other IL-1 signalling intermediaries such as 
soluble IL-1 R-associated kinase-4 (IRAK-4) or PDGF. The work presented 
failed to detect any IL-1 protein in the vessel wall after stenting. This seems 
unlikely, as following angioplasty IL-1 protein levels are detectable. A failure 
to detect any IL-1 protein in this case is likely to be secondary to processing 
difficulties and more work is needed to refine this technique. Better antibodies 
for IL-1 detection may also be required. 
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It is not surprising that the action of IL-1 and hence the mode of delivery of IL-
1 ra may need to be different in the case of PTCA and stent. There is a major 
physical difference between the two interventions in that following stent 
insertion, the metal is left in situ. Compare this to balloon angioplasty where 
the balloon is inflated and then deflated, removing the inflammatory stimulus. 
Chronic stretch itself may be driving the prolonged inflammatory stimulus. 
The effect of stretch on up-regulation of inflammatory cytokines in the context 
of coronary stenting also needs further work. 
The long time point studied in this work with 28 days of IL-1 ra therapy and 
vessel harvesting at 90 days shows that suppression of neointima is 
maintained. It therefore seems likely that in the pig model, 28 days of drug is 
enough to inhibit the chronic inflammation induced by the stent struts and to 
prevent the rebound effect previously seen with cessation of IL-1 ra therapy. 
i 
Questions exist as to the comparability between human and animal studies. 
The stages of healing in the two are very similar however they differ in the 
temporal response, which is prolonged in humans. The life span of a human 
is more than 70 years, compared with a pig lifespan of 16 years. Differential 
rates of healing may be proportional to longevity [127]. Caution must 
therefore still exist as the negative results seen in the pig with Sirolimus and 
Paclitaxel at 90 days mean that long term follow up in the human is imperative 
as it may take years for any catch up to be seen. 
217 
Further work is also planned to determine whether IL-1 ra can be delivered 
from a stent platform. IL-1 ra differs from the cytostatic agents in use in that it 
is a protein and therefore susceptible to alterations in both structure and 
activity by changes in conditions such as temperature. The combination of 
such a molecule with a polymer may reduce its biological activity or render it 
inert. Initial experiments will focus on combining IL-1 ra with a polymer and 
then demonstrating that in combination, IL-1 ra will still bind to IL-1 R1. In 
order to do this, a combination of IL-1 ra and a drug-delivery 'polymer will be 
attached to a BIAcore sensor chip and then IL-1 R1 flowed over the chip to 
determine whether binding still occurs. 
If the IL-1 ra can be combined with a polymer and still bind to the IL-1 R1 then 
the next step will be to determine whether it has maintained its inhibitory 
activity. To do this, a skin bioassay will be used. A stent will be coated in IL-
I 
1 ra and polymer and then small sections of that stent placed under the skin of 
a pig. Intradermal injections of IL-1 ~ will be performed on top of the stent and 
neutrophil recruitment assessed. 
Delivery of agents from a stent-based system can be manipulated by altering 
the properties of the polymer to achieve a slow or fast release of drug. Stents ' 
can be 'top-coated' to delay drug delivery. Making the polymer more 
hydrophobic prolongs the time over which a drug is eluted. As IL-1 ra is highly 
water soluble, it is almost certain that some form of topcoat will be necessary. 
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If IL-1 ra can be successfully bound to a polymer and maintain its inhibitory 
activity, subsequent experiments will involve using the porcine model to 
determine whether stent-based delivery of IL-1 ra is as potent an inhibitor of 
restenosis as systemic delivery. A consensus group has recently produced 
guidelines for the evaluation of drug-eluting stent in preclinical studies [128]. 
Suggested requirements from the document include, in vitro and in vivo 
pharmacokinetics of drug delivery, dose justification and then the use of 
animal models to determine efficacy. The use of either a pig model or a rabbit 
iliac artery model is suggested with appropriate controls to include bare-metal 
stents and coating only. The effect of overlapping stents must be evaluated 
and stent efficacy assessed by absent thrombosis and neointimal reduction. 
-
Time points to be assessed include an early one, i.e. 3 or 7 days, 28-days and 
a late time-point at 3 or 6 months. Necropsy evaluation must be performed 
and all unexpected and premature deaths studied. Arteries should be 
perfusion fixed and details of the detailed histopathologic and 
histomorphometric analyses required are given. Although intended only as a 
guide, it is likely that all the information requested will be necessary to fully 
evaluate any new drug-eluting stent. 
In conclusion, IL-1 ra has beneficial effects upon the coronary artery response 
to injury. Following PTCA, it results in 23% less neointima formation and 
following stenting, results in > 35% less neointima for the duration of the 
infusion. If the infusion is continued for 28 days and the vessels harvested at 
90 days then unlike the cytostatic agents studied, neointima formation 
remains suppressed. The results obtained indicate that the duration of such 
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therapy needs to be for 28 days. The work presented here, shows for the first 
time that a purely anti-inflammatory agent can be used to modulate the 
porcine coronary artery response to injury. This agent causes prolonged 
inhibition of neointima formation at 90 days, unlike Sirolimus and Paclitaxel. 
Potential therapeutic use of this agent to modify vascular proliferative 
responses in the human, specifically to prevent restenosis following 
intracoronary stenting looks promising and further work is underway to 
determine whether this work (using a porcine model) translates into an 
effective treatment for man. 
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TECHNICAL APPENDIX 
A. REAGENTS AND STOCK SOLUTIONS 
A.1 BIAcore Reagents and Stock Solutions 
BUFFER PREPARATION 
Immobilization buffer 10mM sodium acetate, pH to 5.0 
Running buffer 015M HEPES buffered saline, 3.4mM 
EDTA, 0.05% Tween 20, pH to 7.4 
A.2 RNA Reagents and Stock solutions 
All RNA was extracted using the RNAeasy kit from Qiagen. The 
manufacturers give no details of the buffers. 
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A.3 Protein Stock Reagents and Buffers 
SOLUTION PREPARATION 
2X SOS protein sample loading buffer 1 ml glycerol, O.Sml beta-
mercaptoethanol, 3ml1 0% SOS 
1.2Sml 1 M Tris-HCI pH 6.7 
1-2mg bromophenol blue. 
Store frozen in 200j.l1 aliquots. 
RIPA lysis buffer (1 % NP-4010.S% 1 ml NP-40, O.Sg sodium 
sodium deoxycholate/0.1 % SOS) deoxycholate, O.Sml 20% SOS. 
Add PBS to 100ml 
Store at 4°C 
NP-40 lysis buffer (1S0mM NaCI/1 % 0.88g NaCI, 1 ml NP-40 (BOH), 
NP-40/SOmM tris-CI, pH8.0) 0.604g Tris. Add water to 80 mls 
pH to 8.0 and adjust final volume to 
100m!. Store at 4°C 
1 M Tris-HCI pH 6.8 121.1 9 Tris in 800mls water 
pH to 6.8 with concentrated HCL 
Adjust final vol to 1 litre 
1.SM Tris-HCI pH 8.8 181.Sg Tris in 800mls water 
pH to 8.8 with concentrated HCL 
Adjust final vol to 1 litre 
10X Tris-glycine-SOS running buffer 30.3g Tris, 1909 glycine, 100mls 10% 
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(250mM Tris/250mM glycine/10% SOS, water to 1 litre. Oilute to 1X 
SOS) running buffer before use. 
Towbin transfer buffer (39mM 1.45g glycine, 2.9g Tris, 0.185g SOS, 
glycine/48mM Tris/0.037% SOS/20% water to 400mls. 
methanol) Just before use add methanol (BOH) 
to a final volume of 20%. Store at 
room temperature 
10% APS (ammonium persulphate) 0.1 gAPS, 1 ml water. Store in 201-11 
aliquots at -20°C 
Coomassie blue solution 1 9 Coomassie blue R250 (BOH), 
450mls methanol, 450 mls water, 
1 OOmis glacial acetic acid 
Oestain solution 450mls methanol, 450 mls water, 
,) 
100mls glacial acetic acid 
Blocking buffer 20g Marvel, 500mls PBS 
0.1 M phenylmethylsulfonylfluoride 0.1742g PMSF (Sigma), 10mls 
(PMSF) isopropanol (BOH). Store at -70°C in 
5001-11 aliquots 
A.4 Plasmid Reagents and Stock Solutions 
BUFFER COMPOSITION 
P1 50mM Tris-CI, pH8.0; 10mM EOTA; 
100l-lg/mi Rnase A 
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P2 200mM NaOH, 1 % SDS (w/v) 
P3 3.0M potassium acetate, pHS.S 
OBT 7S0mM NaCI; SOmM MOPS, pH7.0; 
1S% isopropanolol (v/v); 0.1S% Triton 
X-100 (v/v) 
OC 1.0M NaCI; SOmM MOPS, pH7.0; 
1S% isopropanolol (v/v) 
OF 1.2SM NaCI; SOmM Tris-CI, pHS.S; 
1S% isopropanolol (v/v) 
ON 1.6M NaCI; SOmM MOPS, pH7.0; 
1S% isopropanolol (v/v) 
.-
TE 10mM Tris-CI, pHS.O; 1 mM EDT A 
STE 100mM Nacl; 10mM Tris-CI, pHS.O; 
( ) 
1mM EDTA 
FWB2 (wash buffer) 1 M potassium acetate pHS.O 
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B. DNA I RNA CONCENTRATION CALCULATIONS 
B.1 RNA Concentration Calculation 
A2601A28o = 1.8 - 2.0 for a pure RNA preparation 
A260 1.0 = 40l-/g RNA per 1 ml 
[RNA] I-/g/l-/l = A260 x dilution factor x 0.04 
B.2 Oligonucleotide Concentration Calculation 
A260 1 = 331-/g single stranded DNA per ml 
[DNA oligo] I-/g/l-/l = A260 x dilution factor x 0.033 
B.3 Molar concentration calculation 
Moles = [g/l] 1 molecular weight of oligo 
B.4 DNA Concentration calculation 
A26o/A28o = 1.8 for a pure DNA preparation 
A260 1.0 = 50l-/g double stranded DNA per ml 
[DNA] I-/g/l-/l = A260 x dilution factor x 0.05 
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C. PROTEIN ELECTROPHORESIS 
C.1 Resolving Gel Preparation 
Sterile water 3.4ml 
30% stoek aerylamide* 7.5ml 
1.5M Tris pH 8.8 3.8ml 
10% SOS 150IJI 
10% APS** 150IJI 
TEMEO*** 61J1 
*Sio-Rad, molar ratio of bisaerylamide:aerylamide is 1 :29. 
**Ammonium persulphate, (SOH). 
***N,N,N, N'-tetramethylethylenediamine, (Sigma). 
C.2 Stacking Gel Preparation 
Sterile water 
30% stoek aerylamide 
1.5M Tris-CI pH 6.8 
10% SOS 
10% APS 
TEMEO 
3.4ml 
830IJI 
630IJI 
50IJI 
50IJI 
51J1 
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